Abstract:
Compounds of Formula (I): in which R'1, R'2, R'7, R'8, R'9, R'10 and A have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.
This application claims the benefit of United States provisional patent applications Serial No. 60/839,018 filed on August 21, 2006 and Serial No. 60/851,385 filed October 13, 2006, which are incorporated herein by reference in their entirety.

The present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds, to a process for making the compounds and to the use of the compounds in therapy. More particularly it relates to certain 4-substituted phenoxyphenylacetic acid derivatives useful in the treatment and prevention of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis and other inflammatory diseases mediated by prostaglandin D2 (PGD$_2$).

International patent application, publication number WO 2004/058164 discloses inter alia, certain 2-substituted phenoxyphenylacetic acid derivatives that modulate the PGD$_2$-selective receptor CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells), now more commonly referred to as DP2. The compounds are said to be useful in the treatment of immunologic diseases such as asthma and allergic inflammation.

It has now been found that certain 4-substituted phenoxyphenyl acetic acid derivatives bearing a particular substituent meta to the acetic acid moiety are DP2 receptor modulators. As used herein, the term "modulator" includes antagonists.

According to one aspect, the present invention provides a compound of general formula (I):

![Diagram](image)

or a salt thereof, wherein:

R' is Ar'-L'-W-1 A;

L$^2$ is -(CR$^a$RV);

W is -CONR$^3_3$ or -NR$^3b$CO-;

R$^{3a}$ and R$^{3b}$ are each H or methyl;

L$^1$ is -(CR$^4$RV), -(CH=CH)-, or -O(CR$^5$R$^b$) provided that when W is -NR$^3$CO- then L$^1$ is not -(CH=CH)-;

n and m are independently 0, 1 or 2;
[0013] each R, Rb, Rc and Rd is independently H, F, OH, methyl or cyclopropyl, or R and Rb or Rc and Rd together with the carbon to which they are attached form a cyclopropyl ring;

[0014] Ar is phenyl or naphthyl, each of which is unsubstituted or substituted with one or more substituents selected independently from F, Cl, CN, CF3, CHF2, CH2F, SF5, methyl, ethyl, cyclopropyl, t-butyl or OMe, or Ar is 1,2,3,4-tetrahydronaphthyl which is unsubstituted or substituted by methoxy;

[0015] provided that when Ar is naphthyl or 1,2,3,4-tetrahydronaphthyl then n is 0;

[0016] R2 is H, Ci-C6 alkyl, a residue of an amino acid or dipeptide, or CHR(CH2)nRF;

[0017] q is 1 to 6;

[0018] R5 is H, methyl or ethyl;

[0019] R1 is NR8Rb in which R8 and Rb each independently represents a hydrogen atom or a C1-C4 alkyl group, or R8 and Rb together with the nitrogen atom to which they are attached form a 5-6 membered heterocyclic ring optionally containing a second ring heteroatom selected from N and O, wherein said heterocyclic ring is optionally substituted with one or more groups independently selected from Ci-Ce alkyl;

[0020] A is CN, CH2NH2, CH2NR=NC(=O)R s, or CH2NR=SO2R6, Cl, OMe, (MQalkyl, cyclopropyl, H, F, Br, CH2NH(I-4C alkyl), CH2N(I-4C alkyl)2, thienyl, or phenyl which is unsubstituted or substituted with SO2Me;

[0021] R4 and R4b are each H or methyl;

[0022] R5 is Ci-C6 alkyl, CpC6 alkoxy, C3-C6 cycloalkyl, hetAr, or Ar2;

[0023] R6 is C1-C6 alkyl, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, Ar3, or hetAr;

[0024] hetAr is a 6 membered heteroaryl which is unsubstituted or substituted with one or more groups independently selected from a halogen atom and a group of formula -NR8Rb in which each of R8 and Rb independently represents a hydrogen atom or a (1-4C) alkyl group, or together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidinyl or morpholino group;

[0025] hetAr is a 5-6 membered heteroaryl which is unsubstituted or substituted with one or more groups independently selected from C1-C4 alkyl;

[0026] Ar is phenyl which is unsubstituted or substituted with one or more groups independently selected from a halogen atom, CN, SF5, cyclopropyl, a Ci-C4 alkyl group, a C1-C4 alkoxy group and a fluoroCrC4 alkyl group;

[0027] Ar is as defined for Ar;

[0028] R7 and R8 are independently H, methyl, or F;

[0029] R9 is H or methyl; and

[0030] R10 is H or F.
[0031] In certain embodiments, the compound of Formula I has the Formula Ia

![Formula Ia]

wherein:

[0032] \( R^1 \) is \( \text{Ar}^1 \cdot \text{L}^1 \cdot \text{W}^1 \cdot \text{L}^2 \cdot \);

[0033] \( L^2 \) is \(-(\text{CR}^d \text{R}^e)_m\)–;

[0034] \( W \) is \(-\text{CONR}^3\text{b}\) or \(-\text{NR}^3\text{b} \text{CO} \cdot \);

[0035] \( R^3\text{a} \) and \( R^3\text{b} \) are each \( \text{H} \) or methyl;

[0036] \( L^1 \) is \(-(\text{CR}^d \text{R}^e)\text{V} \cdot -(\text{CH} = \text{CH}) \cdot \), or \(-\text{O}(\text{CR}^d \text{R}^e)\) provided that when \( W \) is \(-\text{NR}^3\text{CO} \cdot \) then \( L^1 \) is not \(-(\text{CH} = \text{CH}) \cdot \);

[0037] \( n \) and \( m \) are independently 0, 1 or 2;

[0038] each \( R^0 \), \( R^3 \), \( R^4 \) and \( R^6 \) is independently \( \text{H} \), \( \text{F} \), methyl or cyclopropyl, or \( \text{R}^4 \) and \( \text{R}^5 \) or \( \text{R}^6 \) and \( \text{R}^7 \) together with the carbon to which they are attached form a cyclopropyl ring;

[0039] \( \text{Ar}^1 \) is phenyl or naphthyl, each of which is unsubstituted or substituted with one or more substituents selected independently from \( \text{F} \), \( \text{Cl} \), \( \text{CN} \), \( \text{CF}_3 \), \( \text{CHF}_2 \), \( \text{CH}_2\text{F} \), \( \text{SF}_5 \), methyl, ethyl, cyclopropyl, provided that when \( \text{Ar}^1 \) is naphthyl then \( n \) is 0;

[0040] \( R^2 \) is \( \text{H} \), \( \text{Ci-C}_6 \) alkyl, a residue of an amino acid or dipeptide, or \( \text{CHR}^5(\text{CH}_2)\text{qR}^f \);

[0041] \( q \) is 1 to 6;

[0042] \( R^5 \) is \( \text{H} \), methyl or ethyl;

[0043] \( R^f \) is \( \text{NR}^3\text{bR}^h \) in which \( R^8 \) and \( R^9 \) each independently represents a hydrogen atom or a \( \text{Ci} \)-\( \text{C}_4 \) alkyl group, or \( R^8 \) and \( R^9 \) together with the nitrogen atom to which they are attached form a 5-6 membered heterocyclic ring optionally containing a second ring heteroatom selected from \( \text{N} \) and \( \text{O} \), wherein said heterocyclic ring is optionally substituted with one or more groups independently selected from \( \text{CpC}_6 \) alkyl;

[0044] \( A \) is \( \text{CN} \), \( \text{CH}_2\text{NH}_2 \), \( \text{CH}_2\text{NR}^4\text{bC}(=\text{O})\text{R}^5 \), or \( \text{CH}_2\text{NR}^4\text{bSO}_{2}\text{R}^6 \), \( \text{Cl} \), \( \text{OMe} \), \( (\text{l-4C}) \text{alkyl}, \) cyclopropyl;

[0045] \( R^4\text{b} \) and \( R^4\text{h} \) are each \( \text{H} \) or methyl;

[0046] \( R^5 \) is \( \text{Ci-C}_6 \) alkyl, \( \text{Ci-C}_6 \) alkoxy, \( \text{C}_3\text{-C}_6 \) cycloalkyl, \( \text{hctAr}^1 \), or \( \text{Ar}^2 \);

[0047] \( R^6 \) is \( \text{Ci-C}_6 \) alkyl, \( \text{NH} (\text{Ci-C}_6 \text{ alkyl}), \text{N}(\text{Ci-C}_6 \text{ alkyl})_2 \), \( \text{Ar}^3 \), or \( \text{hctAr}^2 \).
hetAr \(^1\) is a 6 membered heteroaryl which is unsubstituted or substituted with one or more groups independently selected from a halogen atom and a group of formula \(-\text{NR}^a\text{R}^b\) in which each of \text{R}^a and \text{R}^b independently represents a hydrogen atom or a (1-4C) alkyl group, or together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidinyl or morpholino group;

hetAr \(^2\) is a 5-6 membered heteroaryl which is unsubstituted or substituted with one or more groups independently selected from C\(_1\)-C\(_4\) alkyl;

\(\text{R}^2\) is phenyl which is unsubstituted or substituted with one or more groups independently selected from a halogen atom, CN, SF\(_3\), cyclopropyl, a C\(_1\)-C\(_4\) alkyl group, a Ci-C\(_4\) alkoxy group and a fluoroCi-C\(_4\) alkyl group;

\(\text{R}^3\) is as defined for \(\text{R}^2\); and

\(\text{R}^7\) and \(\text{R}^8\) are independently H, methyl.

Compounds according to the present invention have been found to be DF2 modulators and are useful in the treatment of immunologic diseases such as asthma and allergic inflammation.

It will be appreciated that certain compounds according to the invention may contain one or more centers of asymmetry and may therefore be prepared and isolated in a mixture of isomers such as a racemic mixture, or in an enantiomerically pure form.

It will further be appreciated that the compounds of formula (I) or their salts may be isolated in the form of solvates, and accordingly that any such solvate is included within the scope of the present invention.

The compounds of Formula I include pharmaceutically acceptable salts thereof. In addition, the compounds of Formula I also include other salts of such compounds which are not necessarily pharmaceutically acceptable salts, and which may be useful as intermediates for preparing and/or purifying compounds of Formula I and/or for separating enantiomers of compounds of Formula I.

The term "halogen" as used herein includes F, Cl, Br and I.

The terms "CpC\(_4\) alkyl" and "C(C)C\(_6\) alkyl" as used herein refer to a saturated linear or brachcd-chain monovalent hydrocarbon radical of one to four or one to six carbon atoms, respectively. Examples of alkyl groups include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-methyl-1-propyl, 2-buty, 2-methyl-2-propyl, 2,2-dimethylpropyl, 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-1-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-penly, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-diniethyl-2-butyl, and 3,3-dimethyl-2-butyl.

The term "heteroaryl" as used herein refers to a monovalent aromatic radical of a 5-, 6-, or 7-membered ring. Examples of heteroaryl groups include, but are not limited to, pyridinyl,
imidazolyl, imidazopyridinyl, pyrimidinyl, pyrazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, and pyrolyl.

[0060] The term "fluoro-C₄ alkyl" as used herein refers to a C₄ alkyl group wherein one or more of the hydrogens is replaced by a fluorine atom. Examples include CF₃, CH₂F, CHF₂, CH₂CH₂F, CH₂CH₂F₂, CH₂CF₃, CH₂CH₂CHF₂, CH₂CH₂CF₃, CHF(CH₃)₂, CH₂CHF(CH₃)₂, and (he like.

[0061] The term "Ci-C₆ alkoxy" as used herein refers to a Ci-C₆ alkyl group. Exemplary alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, and isobutoxy.

[0062] In one embodiment, W is -CONR³⁻⁻. An example of a particular value for R³⁻⁻ is hydrogen. In one embodiment, W is -NR⁶⁻CO⁻. In one embodiment R⁶⁻⁻ is hydrogen. In another embodiment, R⁶⁻⁻ is methyl. Examples of particular values for W arc CONH, NHCO and N(CH₃)CO.

[0063] In one embodiment, L¹ is -(CR⁸⁻⁰R⁹⁻⁰)ₙ⁻⁻. Examples of particular values for n are 0, 1 and 2.

[0064] In one embodiment, L¹ is a bond.

[0065] In one embodiment, L¹ is -(CR²⁻⁰R³⁻⁰). In certain embodiments, R²⁻⁰ and R³⁻⁰ are hydrogen. In certain embodiments, R²⁻⁰ is OH. In certain embodiments, R²⁻⁰ and R³⁻⁰ together with the carbon atom to which are attached form a cyclopropylidine ring.

[0066] In one embodiment, L¹ is -(CR²⁻⁰R₃⁻⁰)₂⁻⁻. In certain embodiments, R²⁻⁰ and R₃⁻⁰ are hydrogen. In certain embodiments, R²⁻⁰ and R₃⁻⁰ together with the carbon atom to which are attached form a cyclopropylidine ring. In certain embodiments, R²⁻⁰ and R₃⁻⁰ are attached to the same carbon. In other embodiments, R²⁻⁰ and R₃⁻⁰ are attached to different carbon atoms.

[0067] Examples of particular values for L¹ are a bond, -CH₂⁻⁰, -CH₂CH₂⁻⁰ and cyclopropylidineCH₂⁻⁰.

(0068) A further example of L¹ includes CH(OH)CH₂⁻⁰.

[0069] Further examples of V include cyclopropylidine groups, which can be represented by the following structures:

\[
\begin{array}{c}
\text{O} \\
\text{S} \\
\text{O}
\end{array}
\]

[0070] In one embodiment, L¹ is -O(CR²⁻⁰R₃⁻⁰). An exemplary embodiment is -OCH₂⁻⁰.

[0071] Referring to L², examples of particular values for m are 0 and 1. Examples of particular values for L² are a bond and -CH₂⁻⁰.

[0072] In certain embodiments, the sum of m and n is 0, 1 and 2. Particular mention is made of compounds in which the sum of m and n is 0 or 2.

[0073] Examples of values for -L²-W⁻⁻L₃⁻⁻ include -CONH⁻⁻, -CH₂CONH⁻⁻, -CH₂CH₂CONH⁻⁻, -CONHCHR, -CH₂CONHCH₂⁻⁻, -NHCO⁻⁻, -CH₂NHCO⁻⁻, -NHCOCH₂⁻⁻, -CH₂CH₂NHCO⁻⁻,
Further examples of values for -L'W-L''- include -CH(OH)CH$_2$NHCO- and -cyclopropyldeneNHCO-.

Particular values of -L'W-L''A -CONH-, -NHCO-, -CH$_2$NHCO-, -NCOCH$_2$-, -CH$_2$CH$_2$NHCO-, -CH$_2$NHCOCH$_2$-, -CH$_2$CH$_2$NHCOCH$_2$-, -CH$_2$N(CH$_3$)COCH$_2$-, cyclopropyldeneCH$_2$NHCO, -CH(OH)CH$_2$NHCO- and -cyclopropyldeneNHCO-.

In one embodiment, A is CN.

In one embodiment, A is H.
7

[0085] In one embodiment, A is selected from F, Br and Cl.

[0086] In one embodiment, A is selected from (1-4)alkyl. Particular examples include methyl and ethyl.

[0087] In one embodiment, A is cyclopropyl.

[0088] In one embodiment, A is selected from CH₂NH₂, CH₂NH(I-C alkyl), and CH₂N(MC alkyl)₂. Particular examples include CH₂NH₂ and CH₂NMe₂.

[0089] In one embodiment, A is thieryl. In a particular embodiment, A is 2-hieryl.

[0090] In one embodiment, A is phenyl which is unsubstituted or substituted with SO₂Me. Particular examples include phenyl, 3-methylsulfonylphenyl, and 4-methylsulfonylphenyl.

[0091] In one embodiment, A is CH₂NR⁺C(=O)R⁵. An example of a particular value for R⁴⁺ is hydrogen. In one embodiment, R⁵ is hetAr⁺. An example of a particular value for a heteroaryl group represented by hetAr⁺ is a pyridyl group. Examples of optional substituents on the heteroaryl group are NH₂, Cl, and pyrrolidinyl.

[0092] In another embodiment, R⁵ is Ci-Ce alkyl; CpC₆ alkoxy; C₃-C₆ cycloalkyl; pyridyl which is unsubstituted or substituted by a halogen atom or a group of formula -NR⁶SO₂ in each of R⁵ and R⁶ independently represents a hydrogen atom or a (1-4) alkyl group, or together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidinyl or morpholino group; or a phenyl group that is unsubstituted or substituted by one or two halogen atoms.

[0093] Examples of particular values for R⁵ are methyl, methoxy, cyclohexyl, pyrid-3-yl, pyrid-4-yl, 6-chloro-pyrid-3-yl, 6-amino-pyrid-3-yl, 6-pyrrolidin-l-y1pyrid-3-yl or 4-fluorophenyl. An additional example of R⁵ is 6-dimethylaminopyrid-3-yl.

[0094] In one embodiment, A is CH₂NR⁺C(=O)R⁵. An example of a particular value for R⁶⁻ is hydrogen. In one embodiment, R⁶ is hetAr⁻. Examples of particular values for a heteroaryl group represented by hetAr⁻ are an imidazolyl and a pyridyl group. Examples for optional substituents on the heteroaryl group are Ci-C₆ alkyl, for example methyl.

[0095] In another embodiment, R⁶ is Ci-C₆ alkyl, NH(Ci-C₆ alkyl), N(Ci-C₆ alkyl)₂, a phenyl group that is unsubstituted or substituted by one or two halogen atoms, pyridyl or imidazolyl that is unsubstituted or substituted with a Ci-C₃ alkyl group.

[0096] Examples of particular values for R⁶ are methyl, dimethylamino, 4-fluorophenyl, 2,4-dichlorophenyl, pyrid-3-yl and 1-methylimidazol-5-yl. An additional example of R⁶ is pyrid-4-yl.

[0097] Examples of particular values for A are acetamidomethyl, cyclohexylamidomethyl, methoxycarbonylamidomethyl, picolinamidomethyl, nicotinamidomethyl, isonicotinamidomethyl, 6-chloropyrid-3-ylamidomethyl, 6-aminopyrid-3-ylamidomethyl, 6-pyrroldin-l-y1pyrid-3-ylamidomethyl, 4-fluorobenzamidomethyl, methylsulfonamidomethyl, N,N-
dimethylsulfamoylamino, 4-fluorophenylsulfonamidomethyl, 2,4-dichlorophenyl-
sulfonamidomethyl, 1-methylimidazol-5-ylsulfonamidomethyl and pyrid-3-ylsulfonamidomethyl, which can be represented by the following structures, respectively:

(0098J) Particular mention is made of acetamidomethyl, cyclohexylamidomethyl, methoxycarbonylaminomethyl, picolinamidomethyl, nicotinamidomethyl, isonicotinamidomethyl, 4-fluorobenzamidomethyl, methylsulfonamidomethyl, N,N-dimethylsulfamoylamino, 4-fluorophenylsulfonamidomethyl, 2,4-dichlorophenylsulfonamidomethyl and pyrid-3-ylsulfonamidomethyl.

[0099J] Particular values for A also include 6-dimethylaminopyrid-3-ylamidomethyl, 2-(4-fluorophenylsulfonamido)acetamidomethyl, dimethylaminomethyl and (N-methylmethylsulfonamido)methyl, which can be represented by the following structures, respectively:

(00100) Examples of particular values for R² when it represents a CpC₆ alkyl group are methyl, ethyl, propyl, isopropyl and t-butyl.
(00101) In one embodiment, R² is CH₅(CH₂)₉R'. Examples of values for R' are hydrogen and methyl. In one embodiment, R² is di(l-4C)alkylamino, morpholino, or piperazinyl optionally substituted with (l-4C)alkyl. Examples of particular values for R' are dimethylamino, diethylamino, morpholino, piperazinyl and 1-methylpiperazinyl. Additional examples include NH₂ and NHMe.
Examples of particular values for $R^2$ when it represents $\text{CHR}^c(\text{CH}_2)^qR^f$ are:

In one embodiment, $R^2$ is hydrogen.

On one embodiment, both $R^7$ and $R^8$ are $H$. In certain embodiments, $R^7$ is $H$ and $R^8$ is methyl. In other embodiments, each of $R^7$ and $R^8$ is methyl.

According to another aspect, the present invention provides a process for the preparation a compound of formula (I) or a salt thereof as defined hereinafter, which comprises:

(a) for a compound of formula (I) in which $A$ is CN, $R^7$ and $R^8$ are independently $H$ or Me, and $R^{10}$ is $H$ or $F_3$ reacting a corresponding compound having the formula:

\[
\begin{align*}
&\text{in which } P^1 \text{ represents a hydrogen atom or a carboxyl protecting group and } Z^1 \text{ represents a leaving atom or group, with a corresponding compound having the formula}
\end{align*}
\]

(II)

in which $R^{10}$ is $H$ or $F$ in the presence of a base; or

(b) for a compound of formula (I) in which $A$ is $-\text{CH}_2\text{NH}_2$, $R^{10}$ is $H$, and $R^7$ and $R^8$ are independently $H$ or Me, reducing a corresponding compound formula (IV)
in which $P^2$ is as defined for $P^1$; or

[OOIOS] (c) for a compound of formula (I) in which $A$ is $\text{CH}_2\text{NH}_2$, $R^7$ and $R^8$ are independently H or Me, and $R^{10}$ is H, cleaving a corresponding compound of formula (V)

![Compound V](image1)

in which $P^3$ is as defined for $P^1$; or

(00109) (d) for a compound of formula (I) in which $A$ is $\text{CH}_2\text{NR}^4\text{C}(=\text{O})\text{R}^3$ or $\text{CH}_2\text{NR}^4\text{SO}_2\text{R}^6$, $R^7$ and $R^8$ are independently H or Me, and $R^{10}$ is H, reacting a corresponding compound of formula (VI)

![Compound VI](image2)

in which $P^4$ is as defined for $P^1$; with a compound of formula $\text{R}^3\text{COZ}^2$ or $\text{R}^6\text{SO}_2\text{Z}^3$, respectively, in which $Z^2$ and $Z^3$ each represents a leaving atom or group; or

[00110] (e) for a compound of formula (I) in which $R^7$ and $R^8$ are independently H or Me, and $R^{10}$ is H, coupling a compound of formula (VII)

![Compound VII](image3)
in which \( P^5 \) is as defined for \( P^1 \), \( A^2 \) represents \( A \) or a protected form thereof and \( R'^{10} \) represents \( H \)-\( X^0 \). 
\( L^2 \) in which \( X^0 \) represents \( H \text{N} \) or \( \text{OC}(=\text{O}) \), or a reactive derivative thereof; with a compound of formula (VIII)

\[
\text{Ar}^\\text{'}-\text{L}^\\text{'}-\text{XNH}
\]

(VIII)

in which \( X^b \) represents \( \text{C}(=\text{O})\text{O} \) or \( \text{NH} \), or a reactive derivative thereof; or

[00111]  (0) for a compound of formula (I) in which \( A \) is \( H \), \( F \) or \( Cl \), \( R^7 \) and \( R^8 \) are independently \( H \) or \( Me \), and \( R^{10} \) is \( H \), coupling a corresponding compound having the formula (IX)

\[
\text{OP}^6
\]

(IX)

in which \( A^3 \) is \( H \), \( F \) or \( Cl \), and \( P^6 \) is as defined for \( P^1 \), with a corresponding compound having the formula (X)

\[
\text{OP}^6
\]

(X)

wherein \( E \) is an electron withdrawing group, in the presence of a base; and if desired removing said electron withdrawing group; or

[00112]  (g) for a compound of formula (I) in which \( A \) is \( \text{OMe} \) or \( (1-4\text{C})\text{alkyl} \), \( R^7 \) and \( R^8 \) are independently \( H \) or \( Me \), and \( R^{10} \) is \( H \), coupling a corresponding compound having the formula (XI)
in which \( A^4 \) is OMe or (1-4C)alkyl, respectively, and \( P^7 \) is as defined for \( P^1 \), with a corresponding compound having the formula (XII)

\[
\text{(XI)}
\]

in the presence of a base, in which \( Z^4 \) represents a leaving atom or group, and \( R^{1x} \) represents an electron withdrawing group convertible into a group \( R^1 \); or

[00113] (h) for a compound of formula (I) in which \( A \) is Br or cyclopropyl, \( R^7 \) and \( R^8 \) are H, and \( R^{10} \) is H, coupling a corresponding compound having the formula (XIV)

\[
\text{(XII)}
\]

in which \( Z^5 \) is a leaving group or atom, with a compound having the formula (XV)

\[
\text{(XIV)}
\]

in the presence of a base, followed by converting the carbonyl group to a carboxyl group; or

[00114] (i) for a compound of formula (I) in which \( A \) is methyl, thienyl, phenyl, or phenyl substituted with SO\(_2\)Me, \( R^9 \) is H; \( R^7 \) and \( R^8 \) are independently H or Me, and \( R^{10} \) is H, reacting a corresponding compound having the formula (XVI)
with a compound having the formula $A^5\text{-}ZnX$, in the presence of a palladium (O) catalyst, or with a compound having the formula $A^5\text{B(OH)}_2$ in the presence of a base and a palladium (O) catalyst, where $A^5$ is methyl, Ihienyl, phenyl, or phenyl substituted with SO$_2$Me and X is a halide; or

(j) for a compound of formula O) in which $R^7$ is F, $R^8$ is H, and $R^{10}$ is H, treating a corresponding compound having the formula (XVII)

with hydrogen fluoride;

(k) for a compound of Formula (I) in which A is CH$_2$NH(I - 4C alkyl) or, CH$_2$N(I - 4C alkyl)$_2$, $R^7$ and $R^8$ are independently H or Me, and $R^{10}$ is H, reacting a corresponding compound having the formula
with an aldehyde having the formula HC(O)(I -4C alkyl); and removing any protecting group or groups and, if desired, forming a salt.

(00117) Referring to process (a), the leaving atom or group represented by \( Z^1 \) may be, for example, a halogen atom such as a fluorine atom. The carboxyl protecting group may be any convenient carboxyl protecting group, for example as described in Greene & Wuts, eds., "Protecting Groups in Organic Synthesis", John Wiley & Sons, Inc. Examples of carboxyl protecting groups include (1-6C)alkyl groups, such as methyl, ethyl and t-butyl. The base may be, for example, an alkali metal hydride or carbonate, such as sodium hydride, sodium carbonate or potassium carbonate, or a tertian' amine, such as triethylamine or N,N-diisopropylethylamine. Convenient solvents include amides, sulfoxides and nitriles, such as DMF, DMSO or acetonitrile. The reaction can be performed at an elevated temperature, such as in the range of from 50 to 150 °C.

(00118) Compounds of formula (II) are known or can be prepared from the corresponding 3-halo compound, such as a 3-bromo compound, by treatment with CuCN.

[00119] Referring to process (b), the compound of formula (IV) can be reduced by hydrogenation in the presence of a Group VIII metal catalyst, such as Raney Ni with methanol/ammonia. The reaction can be conducted at a temperature in the range of from 0 to 100 °C.

[00120] Referring to process (c), the dioxoisoindolinyl group can be cleaved using HBr and acetic acid or hydrazine.

[00121] Compounds of formula (V) can be prepared by reacting a compound of formula (XIII)

![Diagram](XIII)

with a compound of formula (XII)

![Diagram](XII)

in the presence of a base, in which \( Z^4 \) represents a leaving atom or group, such as a fluorine atom, and \( R^{15} \) represents an electron withdrawing group convertible into a group \( R^1 \), for example a nitro group that can be reduced to an amino group and then acylated. The base may be, for example, an
Compounds of formula (IX) can be prepared by reacting 4-hydroxyphenylacetic acid with 2-(hydroxymethyl)isoindoline-1,3-dione in the presence of a sulfonic acid, such as methanesulfonic acid, and followed if desired by introducing a protecting group P³.

Referring to process (d), the leaving atom or group represented by Z² and Z³ may be, for example, a halogen atom such as a fluorine atom. The reaction can be performed in the presence of a base, for example a tertiary amine such as diisopropylethylamine or pyridine. Convenient solvents include halogenated hydrocarbons, such as methylene chloride. The reaction can be conducted at a temperature in the range of from 0 to 100 °C.

Referring to process (e), the coupling of the compound of formula (VII) with a compound of formula (VIII) may be performed using conventional amide bond formation conditions, for example by reacting an amine with a reactive derivative of a carboxylic acid, for example an acid halide, such as an acid chloride. An example of A¹ when it represents a protected form of A is a group of formula -CH₂NR⁺P⁰ in which P⁰ represents an amine protecting group. The amine protecting group may be any convenient amine protecting group, for example as described in Greene & Wuts, eds., "Protecting Groups in Organic Synthesis", John Wiley & Sons, Inc. Examples of amine protecting groups include acyl and alkoxy carbonyl groups, such as t-butoxycarbonyl (BOC).

Referring to process (f), examples of electron withdrawing groups include NO₂. In embodiments wherein the electron withdrawing group is NOₐ, this group can be removed, if desired, by reducing the nitro group to an amino group using any convenient reducing conditions (for example, Zn and NH₄Cl) followed by cleavage of the amino group (for example, by treating the amino compound with isobutyl nitrite).

Referring to process (g), the base may be, for example, an alkali metal hydride or carbonate, such as sodium hydride, sodium carbonate or potassium carbonate. The Z⁴ group represents a suitable leaving atom or group, such as a fluorine atom, and R¹⁺ represents an electron withdrawing group convertible into a group R¹, for example a nitro group that can be reduced to an amino group and then acylated.

Referring to process (h), the leaving atom or group represented by Z⁵ may be, for example, a halogen atom such as a fluorine atom. The base may be, for example, an alkali metal hydride or carbonate, such as sodium hydride, sodium carbonate, or potassium carbonate. Convenient solvents include sulfoxides such as DMSO. The reaction can be performed at elevated temperatures, for example in the range of 50-100 °C, for example at 85 °C. The carbonyl group can
be converted to a carboxyl group by treating the coupling product with methylsulfonyl/methylthiomethane to provide an intermediate having the formula (XVIII)

![Chemical structure image]

(XVIII)

followed by converting the intermediate (XVIII) to the corresponding methyl ester upon treatment with HCl in methanol. The ester can be converted to the corresponding acid under standard hydrolysis conditions.

[00128] Referring to process (i), the halide represented by X can be F, Cl or Br. Convenient solvents include ethers such as THF or dioxane. Suitable palladium (0) catalysts include Pd(PPIb)₄ and bis(tri-t-butylphosphine)palladium (0). A convenient base when compound (XVI) is reacted with a boronic acid reagent includes DBU. The reaction can be performed at elevated temperatures, for example in the range of 50-100 °C, for example 60 °C.

[00129] Referring to process (j), the reaction is conveniently performed in the presence of an amine base, for example pyridine.

[00130] Referring to process (k), the reaction is conveniently performed in the presence of a base, for example a hydride such as sodium cyanoborohydride in an alcohol solvent such as methanol. The reaction is preferably performed in the presence of a catalytic amount of acid, for example acetic acid. The reaction is conveniently performed at ambient temperature.

[00131] The ability of test compounds to act as DP2 receptor modulators may be demonstrated by the assay described in Example A.

[00132] Compounds which are modulators of DP2 are useful in the treatment of diseases or disorders mediated by PGD₂, for example, diseases or disorders associated with overproduction or dysregulation of PGD₂.

[00133] As used herein, the term treatment includes prophylaxis as well as treatment of an existing condition.

[00134] Examples of disorders or diseases that may be treated with compounds according to the invention include immunologic diseases.
Examples of immunologic diseases include allergic inflammatory diseases, such as asthma, atopic dermatitis, allergic rhinitis, seasonal allergies, food allergies, contact hypersensitivity (e.g., nickel sensitivity), hypcr-cosinophilic syndromes, and allergic conjunctivitis.

Additional diseases or disorders which may be treated with the compounds of this invention include inflammatory bowel diseases such as Crohn's disease, ulcerative colitis, ileitis and enteritis, vasculitis, Behcet's syndrome, psoriasis and inflammatory dermatoses such as dermatitis, eczema, urticaria, viral cutaneous pathologies such as those derived from human papillomavirus, HIV or RLV infection, bacterial, fungal and other parasitl cutaneous pathologies, and cutaneous lupus erythematosus, respiratory allergic diseases such as persensitivity lung diseases, chronic obstructive pulmonary disease and the like, autoimmune diseases, such as arthritis (including rheumatoid and psoriatic), systemic lupus erythematosus, type I diabetes, myasthenia gravis, multiple sclerosis, Graves' disease, glomerulonephritis and the like, graft rejection (including allograft rejection and graft-v-host disease), e.g., skin graft rejection, solid organ transplant rejection, bone marrow transplant rejection, fever, cardiovascular disorders such as acute heart failure, hypotension, hypertension, angina pectoris, myocardial infarction, cardiomyopathy, congestive heart failure, atherosclerosis, coronary artery disease, restenosis, thrombosis and vascular stenosis, cerebrovascular disorders such as traumatic brain injury, stroke, ischemic reperfusion injury and aneurysm, cancers of the breast, skin, prostate, cervix, uterus, ovary, testes, bladder, lung, liver, larynx, oral cavity, colon and gastrointestinal tract (e.g., esophagus, stomach, pancreas), brain, thyroid, blood and lymphatic system, fibrosis, connective tissue disease and sarcoidosis, genital and reproductive conditions such as erectile dysfunction, gastrointestinal disorders such as gastritis, ulcers, nausea, pancreatitis and vomiting; neurologic disorders, such as Alzheimer's disease, sleep disorders such as insomnia, narcolepsy, sleep apnea syndrome and Pickwick Syndrome, pain, renal disorders, ocular disorders such as glaucoma, infectious diseases, viral infections such as HIV, and bacterial infections such as sepsis, inflammation, flushing, nasal congestion, and otitis media.

Accordingly, another aspect of this invention provides a method of treating diseases or medical conditions in a mammal mediated by PGD2, comprising administering to said mammal one or more compounds of Formula I or a pharmaceutically acceptable salt or prodrug thereof in an amount effective to treat or prevent said disorder.

The phrase “effective amount” means an amount of compound that, when administered to a mammal in need of such treatment, is sufficient to (i) treat or prevent a particular disease, condition, or disorder mediated by PGD2, (ii) attenuate, ameliorate, or eliminate one or more symptoms of the particular disease, condition, or disorder, or (iii) prevent or delay the onset of one or more symptoms of the particular disease, condition, or disorder described herein.
[00139] The amount of a compound of Formula I that will correspond to such an amount will vary depending upon factors such as the particular compound, disease condition and its severity, the identity (e.g., weight) of the mammal in need of treatment, but can nevertheless be routinely determined by one skilled in the art.

(00140) As used herein, the term "mammal" refers to a warm-blooded animal that has or is at risk of developing a disease described herein and includes, but is not limited to, guinea pigs, dogs, cats, rats, mice, hamsters, and primates, including humans.

(00141) This invention also provides compounds of Formula I for use in the treatment of PGD2-mediated conditions.

(00142) An additional aspect of the invention is the use of a compound of Formula I in the preparation of a medicament for therapy, such as for the treatment or prevention PGD2-mediated conditions.

(00143) The compounds of the present invention can be used in combination with one or more additional drugs, for example an anti-inflammatory compound that works by a different mechanism of action.

(00144) The compounds of the invention may be administered by any convenient route, e.g. into the gastrointestinal tract (e.g. rectally or orally), the nose, lungs, musculature or vasculature or transdermally. The compounds may be administered in any convenient administrative form, e.g. tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches etc. Such compositions may contain components conventional in pharmaceutical preparations, e.g. diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents. If parenteral administration is desired, the compositions will be sterile and in a solution or suspension form suitable for injection or infusion. Such compositions form a further aspect of the invention.

(00145) According to another aspect, the present invention provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined hereinabove. In one embodiment, the pharmaceutical composition includes the compound of formula (I) together with a pharmaceutically acceptable diluent or carrier.

(00146) According to another aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in therapy.

(00147) According to a further aspect, the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament to (real an immunologic disorder, as defined hereinabove.
The following examples illustrate the invention. In the examples described below, unless otherwise indicated all temperatures are set forth in degrees Celsius. Reagents were purchased from commercial suppliers such as Aldrich Chemical Company, Lancaster, TCI or Maybridge, and were used without further purification unless otherwise indicated. Tetrahydrofuran (THF), dichloromethane (DCM, methylene chloride), toluene, and dioxane were purchased from Aldrich in Sure seal bottles and used as received.

The reactions set forth below were done generally under a positive pressure of nitrogen or argon or with a drying tube (unless otherwise stated) in anhydrous solvents, and the reaction flasks were typically fitted with rubber septa for the introduction of substrates and reagents via syringe. Glassware was oven dried and/or heat dried.

1H NMR spectra were obtained as CDCl₃, CD₃OD, D₂O or d₆-DMSO solutions (reported in ppm), using tetramethylsilane (0.00 ppm) or residual solvent (CDCl₃: 7.25 ppm; CD₃OD: 3.31 ppm; D₂O: 4.79 ppm; d₆-DMSO: 2.50 ppm) as the reference standard. When peak multiplicities are reported, the following abbreviations are used: s (singlet), d (doublet), t (triplet), m (multiple.), br (broadened), dd (doublet of doublets), dt (doublet of triplets). Coupling constants, when given, are reported in Hertz (Hz).

Example A

DP-2 binding Inhibition Assay

The coding sequence of human DP2 was introduced into the human Leukemic cell line K562 by electroporation and stable clones expressing DP2 were obtained by limiting dilution followed by cell surface staining with a rat monoclonal antibody specific for human DP2. Membranes were prepared from one of these DP2 expressing clones and used to determine the ability of the compounds of the present invention to inhibit binding of prostaglandin D₂ (PGD₂) to its receptor DP2 by the following procedure. Membranes (1.25 Oₐ/well) were mixed with ³H-labeled PGD₂ and various concentrations of test compounds in 150 µL of binding buffer (50 mM Tris-HCl, pH 7.4, 40 mM MgCl₂, 0.1% bovine serum albumin, 0.1% NaN₃) in 96-well U-bottom polypropylene plates. After incubation for 60 minutes at room temperature, the assay was transferred to a filtration plate (#MAFB; Millipor Corporation, Bedford, MA), and washed three times with binding buffer. Radioactivity was measured by a scintillation counter (TopCount; PerkinElmer Life Sciences, Boston, MA). Nonspecific binding was determined by incubations in the presence of 1 µM unlabeled PGD₂ or 5 DM of a known DP2 antagonist. IC₅₀ values for inhibition of binding are determined for each compound tested from the inflexion point of a standard 4-parameter logistical curve fitted to the values obtained. All compounds disclosed herein had IC₅₀ values less than 1 micromolar.
Example 1

2-(4-(4-(3,4-Dichlorobenzamido)phenoxy)-3-((4-fluorophenylsulfonamido)vinyl)-phenyl)acetic acid

[00152] Step A: 2-(4-hydroxyphenyl)acetic acid (7.0 g, 46 mmol) was diluted with methanesulfonic acid (100 mL) and cooled to -10 ºC. 2-(Hydroxymethyl)isoindoline-1,3-dione (8.2 g, 46 mmol) was added portionwise over 15 minutes. The reaction was allowed to warm to room temperature and stirred overnight. The reaction was poured onto ice and stirred for 1 hour. The reaction mixture was filtered and rinsed with water. The material was air dried overnight and then placed under high vacuum for 5 hours. The material was then taken up in DMF using heat to ensure all the material was in solution. Small amounts of water were added until a precipitate persisted. The mixture was filtered and the solid material corresponded to bis alkylated material. Additional water was added to crash out the 2-(3-((1,3-dioxoisindolin-2-yl)methyl)-4-hydroxyphenyl)acetic acid which was filtered and dried. This material was carried on to the next step without further purification.

[00153] Step B: The product of step A (6.7 g, 22 mmol) was diluted with HBr (21 g, 258 mmol) and acetic acid (20 mL). The reaction mixture was heated to reflux and stirred overnight. The reaction mixture was then cooled to 0 ºC and was neutralized with solid NaOH pellets to pH 10, affording a solution of 2-(3-(aminomethyl)-4-hydroxyphenyl)acetic acid which was used in the next step without further purification.

[00154] Step C: To 2-(3-(aminomethyl)-4-hydroxyphenyl)acetic acid (3.9 g, 21.5 mmol) was added BOC2O (5.40 g, 24.8 mmol) in 30 mL of dioxane. After stirring for 4 hours, the reaction was diluted with ethyl acetate and IN HCl. The organic layer was dried over MgSO4 and concentrated. The solid was taken up in minimal methylene chloride, filtered and rinsed with methylene chloride. The filtrate was concentrated to yield 3.0 g of 2-(3-((tert-butoxycarbonyl)aminomethyl)-4-hydroxyphenyl)acetic acid as a white foam.

[00155] Step D: 2-(3-((tert-Butoxycarbonyl)aminomethyl)-4-hydroxyphenyl)acetic acid (1.6 g, 5.69 mmol) was diluted with THF (10 mL) and methanol (5 mL) followed by the addition of TMSCHN2 (14.2 mL, 28.4 mmol) dropwise. The reaction mixture was stirred for 30 minutes and then diluted with ethyl acetate and water. The layers were separated and the organic layer was dried.
over MgSO₄, filtered and concentrated. The material was purified using a biotage 4OS cartridge eluting with hexanes:ethyl acetate (4:1) yield 860 mg of clear oil that later solidified to methyl 2-(3-((tert-butoxycarbonyl)aminomethyl)-4-hydroxyphenyl)acetate.

**[00156]** Step E: Methyl 2-(3-((tert-butoxycarbonyl)aminomethyl)-4-hydroxyphenyl)acetate (200 mg, 0.677 mmol) was diluted with ACN (2 mL) followed by the addition of K₂CO₃ (206 mg, 1.49 mmol) and 1-fluoro-4-nitrobenzene (0.103 mL, 0.948 mmol). The reaction mixture was heated to reflux (at about 82 °C) and stirred for 5 hours. The reaction mixture was then diluted with ethyl acetate and water. The layers were separated and the organic layer was dried over MgSO₄, filtered and concentrated. The material was purified using a biotage 4OS eluting with hexanes/ethyl acetate (3:1) to yield 242 mg of methyl 2-(3-((tert-butoxycarbonyl)aminomethyl)-4-(4-nitrophenoxy)phenyl)acetate as a clear oil.

**[00157]** Step F: Methyl 2-(3-((tert-butoxycarbonyl)aminomethyl)-4-(4-nitrophenoxy)phenyl)acetate (242 mg, 0.581 mmol) was diluted with THF (3 mL) followed by the addition of Zn dust (38.0 mg, 0.581 mmol). About 2 mL of saturated ammonium chloride was added dropwise. After stirring the reaction for 10 minutes, the reaction mixture was diluted with ethyl acetate and saturated sodium bicarbonate. The layers were separated and the organic layer was dried over MgSO₄, filtered and concentrated to yield 225 mg of methyl 2-(4-(4-aminophenoxy)-3-((tert-butoxycarbonyl)aminomethyl)phenyl)acetate.

**[00158]** Step G: Methyl 2-(4-(4-aminophenoxy)-3-((tert-butoxycarbonyl)aminomethyl)phenyl)acetate (100 mg, 0.259 mmol) was diluted with methylene chloride (3 mL) followed by the addition of 3,4-dichlorobenzoyle chloride (81.3 mg, 0.388 mmol) and N,N-diisopropylethyl amine (0.0451 mL, 0.259 mmol). The reaction was stirred for 3 hours. The reaction mixture was diluted with methylene chloride and water. The layers were separated and the organic layer was dried over MgSO₄, filtered and concentrated. The material was purified using a biotage 12i eluting with hexanes:ethyl acetate (3:1) to yield 130 mg of methyl 2-(3-((tert-butoxycarbonyl)aminomethyl)-4-(3,4-dichlorobenzamido)phenoxy)phenyl)acetate.

**[00159]** Step H: Methyl 2-(3-((tert-butoxycarbonyl)aminomethyl)-4-(3,4-dichlorobenzamido)phenoxy)phenyl)acetate (130 mg, 0.232 mmol) was treated with HCl (0.581 mL, 2.32 mmol). After stirring for 3 hours, the material was concentrated to yield 100 mg of methyl 2-(3-(aminomethyl)-4-(3,4-dichlorobenzamido)phenoxy)phenyl)acetate.

**[00160]** Step I: The product of step H (30 mg, 0.065 mmol) was diluted with methylene chloride (1 mL) followed by the addition of 4-fluorobenzene-1-sulfonyl chloride (15 mg, 0.078 mmol) and DIEA (0.024 mL, 0.14 mmol). After stirring the reaction for 4 hours, the reaction mixture was placed directly onto a preparative tic plate 0.5 mm and eluted with hexanes:ethyl acetate (3:1) to
yield 30 mg of methyl 2-(4-(4-(3,4-dichlorobenzamido)phenoxy)-3-((4-fluorophenyl-sulfonamido)methyl)phenyl)acetate.

**Step J:** Methyl 2-(4-(4-(3,4-dichlorobenzamido)phenoxy)-3-((4-fluorophenyl-sulfonamido)methyl)phenyl)acetate (40 mg, 0.065 mmol) was diluted with MeOH (1 mL) followed by the addition of NaOH (0.32 mL, 1.3 mmol). After stirring for 1 hour, the reaction mixture was diluted with ethyl acetate and 2N HCl. The layers were separated and the organic layer was dried over MgSO₄, filtered and concentrated. The material was purified using a 0.5 mm preparative plate eluting with methylene chloride:MeOH:AcOH (90:9:1) to yield 12 mg of the title compound as a solid. ¹H NMR (400 MHz, CDCl₃,CD₃OD) 8.1 (s, 1H), 7.85 (m, 2H), 7.65 (m, 3H), 7.50 (m, 1H), 7.35 (d, 1H), 7.2 (s, 1H), 7.10 (d, 1H), 6.90 (d, 2H), 6.60 (d, 1H), 4.20 (s, 2H), 3.45 (s, 2H).

**Example 2**

2-(4-(4-(3,4-Dichlorobenzamido)phenoxy)-3-(methylsulfonamidomethyl)phenyl)acetic acid

Prepared by the method of Example 1, substituting 4-fluorobenzene-1-sulfonyl chloride in Step H with methanesulfonyl chloride. ¹H NMR (400 MHz, DMSO) 12.4 (s, 1H), 10.4 (s, 1H), 8.20 (m, 1H), 7.95 (m, 1H), 7.85 (d, 1H), 7.75 (d, 2H), 7.55 (t, 1H), 7.4 (m, 1H), 7.19 (m, 1H), 7.05 (d, 2H), 6.8 (d, 1H), 4.2 (d, 2H), 3.55 (s, 2H), 2.85 (s, 3H).

**Example 3**

2-(4-(4-(3,4-Dichlorobenzamido)phenoxy)-3-(2,4-dichlorophenylsulfonamido)methyl)-phenyl)acetic acid

Prepared by the method of Example 1, substituting 4-fluorobenzene-1-sulfonyl chloride in Step H with 2,4-dichlorobenzyl-1-sulfonyl chloride. ¹H NMR (400 MHz, CDCl₃,CDJOD) 8.1 (s, 1H), 7.85 (m, 2H), 7.65 (m, 3H), 7.50 (m, 1H), 7.35 (d, 1H), 7.2 (s, 1H), 7.10 (d, 1H), 6.90 (d, 2H), 6.60 (d, 1H), 4.20 (s, 2H), 3.45 (s, 2H).
Example 4

2-(4-(4-(3,4-Dichlorobenzamido)phenoxy)-3-(nicotinamidomethyl)phenyl)acetic acid

(00164) Step A: 4-Aminophenol (1.9 g, 17 mmol) was diluted with DMF (40 mL) followed by the addition of pyridine (0.978) (1.4 mL, 17 mmol) and 3,4-dichlorobenzoyl chloride (3.0 g, 14 mmol) in 5 mL of DMF. After stirring for 12 hours, the reaction mixture was diluted with ethyl acetate and 2N HCl. The aqueous layer was extracted once with ethyl acetate. The organics were combined, washed with water, brine, dried over MgSO₄, filtered and concentrated onto silica gel. The material was purified using a biotage 4OM column eluting with hexane:ethyl acetate (9:1) using 2 L and then (60:40) IL to yield 3,4-dichloro-N-(4-hydroxyphenyl)-benzamide (1.5 g, 37% yield) as a white solid.

(00165) Step B: tert-Butyl 2-(3-cyano-4-fluorophenyl)acetate (2.0 g, 8.5 mmol) and the product of step A (2.9 g, 10 mmol) were diluted with DMSO (22 mL) followed by the addition of potassium carbonate (1.4 g, 10 mmol). The reaction was heated to 125 °C and stirred for 12 hours. The reaction mixture was then cooled to room temperature, diluted with ethyl acetate and 10% aqueous sodium carbonate. The layers were separated and the organic layer was washed with 10% aqueous sodium carbonate two more times followed by water and brine. The organic material was dried over MgSO₄, filtered and concentrated. The material was purified using a biotage 4OM column eluting with hexanes:ethyl acetate (8:2) to yield tert-butyl 2-(3-cyano-4-(4-(3,4-dichlorobenzamido)phenoxy)phenyl)acetate (2.5 g, 59% yield) as a white solid.

(00166) Step C: The product of step B (100 mg, 0.201 mmol) was diluted with 7N ammonia/methanol (10 mL), followed by addition of ethyl acetate (10 mL). Once the material dissolved, Raney Nickel (1.72 mg, 0.0201 mmol) was added and the reaction was purged three times with a balloon of hydrogen. After stirring for 12 hours, the reaction mixture was filtered through a GF/F filter and concentrated. The residue was purified using a biotage 12i column eluting with methylene chloride:MeOH:NH₄OH (90:9:1) to yield tert-butyl 2-(3-(aminomethyl)-4-(4-(3,4-dichlorobenzamido)phenoxy)phenyl)acetate (100 mg, 99.2% yield) as a clear oil.
Step D: The product of step C (0.050 g, 0.997 mmol) was dissolved into 1 mL of DCM in a small test tube. Pyridine (0.017 g, 0.219 mmol) and nicotinoyl chloride (0.0195 g, 0.110 mmol) were added, and the reaction mixture was stirred for 12 hours. The reaction mixture was then diluted with methylene chloride and water. The methylene chloride layer was separated and loaded directly onto a biotage 12i column cluting with methylene chloride:MeOH (95:5) to yield tert-buryl 2-(4-(4-(3,4-dichlorobenzamido)phenoxy)-3-(nicotinamidomethyl)phenyl)-acetate (44 mg, 73% yield) as a clear oil.

Step E: The product of step D (44 mg, 0.073 mmol) was diluted with methylene chloride:TFA (1:1) and stirred for 3 hours. The reaction mixture was concentrated, taken up in ether and sonicated. The solid was filtered, rinsed with ether and dried under vacuum to yield the title compound (35 mg, 88% yield) as white solid. \(^1\)H NMR (400 MHz, CDCl\(_3\)/CD\(_3\)OD) 8.75 (m, 1H), 8.65 (m, 1H), 8.15 (m, 1H), 8.10 (m, 1H), 8.0 (m, 1H), 7.60 (m, 3H), 7.45 (m, 1H), 7.20 (m, 1H), 6.95 (d, 2H), 6.90 (d, 1H), 4.65 (m, 2H), 3.62 (s, 2H).

Example 5

2-(4-(4-(3,4-Dichlorobenzamido)phenoxy)-3-((N,N-dimethylsulfamoylamino)methyl)-phenyl)acetic acid

Prepared by the method of Example 4, substituting nicotinoyl chloride in Step D with dimethylsulfamoyl chloride. \(^1\)H NMR (400 MHz, CDCl\(_3\)/CD\(_3\)OD) 8.05 (s, 1H), 7.80 (m, 1H), 7.65 (m,2H), 7.55 (d, 1H), 7.35 (m, 1H), 7.18 (m, 1H), 7.00 (d, 2H), 6.82 (d, 1H), 4.25 (s, 2H), 3.60 (s, 2H), 2.75 (s, 6H).
Example 6

2-(4-(4-(3,4-Dichlorobenzamido)phenoxy)-3-(methylsulfonamidomethyl)phenyl)acetic acid

Prepared by the method of Example 4, substituting nicotinoyl chloride in Step D with methanesulfonyl chloride. $^1$H NMR (400 MHz, δ-DMSO) 12.4 (s, 1H), 10.4 (s, 1H), 8.20 (m, 1H), 7.95 (m, 1H), 7.85 (d, 1H), 7.75 (d, 2H), 7.55 (t, 1H), 7.4 (m, 1H), 7.19 (m, 1H), 7.05 (d, 2H), 6.8 (d, 1H), 4.2 (d, 2H), 3.55 (s, 2H), 2.85 (s, 3H).

Example 7

2-(3-(Cyclohexanecarboxamidomethyl)-4-(4-(3,4-dichlorobenzamido)phenoxy)phenyl)-acetic acid

Prepared by method of Example 4, substituting nicotinoyl chloride in Step D with cyclohexanecarbonyl chloride. $^1$H NMR (400 MHz, CDCl$_3$, CD$_3$OD) 8.10 (m, 1H), 7.80 (m, 1H), 7.65 (d, 2H), 7.55 (d, 1H), 7.25 (m, 1H), 7.15 (d, 1H), 6.95 (d, 2H), 6.85 (d, 1H), 2.10 (m, 1H), 1.6-1.8 (m, 5H), 1.2-1.4 (m, 6H).

Example 8

2-(3-(Acetamidomethyl)-4-(4-(3,4-dichlorobenzamido)phenoxy)phenyl)-acetic acid
Prepared by the method of Example 4, substituting nicotinoyl chloride in Step D with acetyl chloride. ¹H NMR (400 MHz, CDCl₃/CD₂OD) 8.10 (m, 1H), 7.80 (m, 1H), 7.60 (m, 3H), 7.30 (m, 1H), 7.15 (m, 1H), 6.95 (d, 2H), 6.85 (d, 1H), 4.42 (s, 2H), 3.40 (s, 2H), 1.95 (s, 3H).

Example 9

2-(4-(4-(3,4-Dichlorobenzamido)phenoxy)-3-(isonicotinamidomethyl)phenyl)acetic acid

Prepared by the method of Example 4, substituting nicotinoyl chloride in Step D with isonicotinoyl chloride. ¹H NMR (400 MHz, CDCl₃/CD₂OD) 8.62 (m, 1H), 8.05 (m, 1H), 7.88 (m, 1H), 7.80 (m, 1H), 7.65 (m, 2H), 7.58 (m, 3H), 7.35 (m, 1H), 7.20 (m, 1H), 6.95 (d, 2H), 6.90 (d, 1H), 4.65 (d, 2H), 3.62 (s, 2H).
Example 10

2-(4-(4-(3,4-Dichlorobenzamido)phenoxy)-3-(4-fluorobenzamido)methyl)phenyl)acetic acid

Prepared by the method of Example 4, substituting nicotinoyl chloride in Step D with 4-fluorobenzoyl chloride. 1H NMR (400 MHz, CD3OD) 8.10 (s, 1H), 7.85 (m, 1H), 7.80 (m, 2H), 7.70 (d, 1H), 7.62 (d, 2H), 7.35 (s, 1H), 7.25 (d, 1H), 7.35 (m, 2H), 6.95 (d, 2H), 6.90 (d, 1H), 4.62 (s, 2H), 3.60 (s, 3H).

Example 11

2-(4-(4-(3,4-Dichlorobenzamido)phenoxy)-3-(picolinamidomethyl)phenyl)acetic acid

Prepared by the method of Example 4, substituting nicotinoyl chloride in Step D with picolinoyl chloride. 1H NMR (400 MHz, CD3OD) 8.60 (d, 1H), 8.10 (m, 1H), 8.05 (m, 1H), 7.95 (m, 1H), 7.85 (m, 1H), 7.70 (d, 1H), 7.60 (d, 2H), 7.55 (m, 1H), 7.35 (m, 1H), 7.20 (d, 1H), 7.00 (d, 2H), 6.85 (d, 1H), 4.64 (s, 2H), 3.60 (s, 2H).

Example 12

2-(4-(4-(3,4-Dichlorobenzamido)phenoxy)-3-((methoxycarbonylamino)methyl)phenyl)-acetic acid
Prepared by the method of Example 4, substituting nicotinoyl chloride in Step D with methyl chloroformate.  $^1$H NMR (400 MHz, CDCl$_3$) 8.10 (m, IH), 7.80 (m, IH), 7.65 (m, 2H), 7.58 (m, IH), 7.30 (m, IH), 7.19 (m, IH), 6.95 (m, 2H), 6.85 (m, IH), 4.40 (s, 2H), 3.65 (s, 5H), 3.60 (s, 2H).

Example 13

2-(4-(4-(3,4-Dichlorobenzamido)phenoxy)-3-((pyridine-3-sulfonamido)methyl)phenyl)-acetic acid

Prepared by the method of Example 4, substituting nicotinoyl chloride in Step D with pyridine-3-sulfonyl chloride.  $^1$H NMR (400 MHz, CDCl$_3$) 8.95 (s, IH), 8.60 (m, IH), 8.10 (m, IH), 7.80 (d, IH), 7.60 (m, 3H), 7.35 (m, IH), 7.22 (m, IH), 7.05 (d, IH), 6.80 (d, 2H), 6.62 (d, IH), 4.25 (s, IH), 3.55 (s, 2H).

Example 14

2-(4-(4-(3,4-Dichlorophenylcarbamoyl)phenoxy)-3-(methylsulfonamidomethyl)phenyl)-acetic acid

Step A: tert-Butyl 2-(3-cyano-4-fluorophenyl)acetate (2.6 g, 11.1 mmol) and methyl 4-hydroxybenzoate (3.36 g, 22.1 mmol) were diluted with DMSO (22 mL) followed by the addition of potassium carbonate (1.83 g, 13.3 mmol). The reaction mixture was heated to 125 °C and stirred for 5 hours. The reaction mixture was diluted with ethyl acetate and 10% aqueous sodium carbonate. The layers were separated and the organic layer was washed with 10% aqueous sodium carbonate two more times followed by water and brine. The organic material was dried over MgSO$_4$, filtered and concentrated. The material was purified using a biotage 40M column eluting with hexanes:ethyl...
acetate (9:1) to yield methyl 4-(4-(2-tert-butoxy-2-oxoethyl)-2-cyanophenoxy)benzoate (2.65 g, 65.3% yield) as a clear oil.

[00179] Step B: The product of step A (2.5 g, 6.80 mmol) was diluted with 10 mL ammonia/niethanol (30 mL) followed by the addition of Raney Nickel (0.0583 g, 0.680 mmol). The reaction mixture was purged three times with hydrogen and stirred for 12 hours. The reaction mixture was then filtered through a GF/F filter and concentrated. The residue was purified using a biotage 4OM column eluting with methylene chloride:MeOH:NH₄OH (90:9:1) to yield methyl 4-(2-(aminomethyl)-4-(2-tert-butoxy-2-oxoethyl)phenoxyl)benzoate (1.87 g, 74.0% yield) as a clear oil.

[00180] Step C: The product of step B (1.87 g, 5.03 mmol) was diluted with methylene chloride (2 mL) followed by the addition of pyridine (0.489 mL, 6.04 mmol) and methanesulfonyl chloride (0.779 mL, 10.1 mmol). After stirring for 12 hours, the reaction mixture was diluted with methylene chloride and 2N HCl, the layers were separated and the organic layer was dried over MgSO₄, filtered and concentrated. The material was purified using a biotage 4OM cartridge eluting with hexancsxthyl acetate (1:1) to yield methyl 4-(4-(2-tert-butoxy-2-oxoethyl)-2-(methysulfonamidomethyl)phenoxy)benzoate (1.53 g, 67.6% yield) as a clear oil.

[00181] Step D: The product of step C (900 mg, 2.00 mmol) was diluted with dioxane (10 mL) followed by the addition of LiOH-H₂O (126 mg, 3.00 mmol) dissolved in water (2 mL). After stirring for 12 hours, the reaction mixture was diluted with ethyl acetate and 2N HCl. The layers were separated and the organic layer was dried over MgSO₄, filtered and concentrated. The material was purified using a biotage 4OM cartridge eluting with methylene chloride:MeOH (95:5) to yield 4-(4-(2-tert-butoxy)-2-oxoethyl)-2-(methylsulfonamido-methyl)phenoxy)benzoic acid (710 mg, 81.4% yield) as a clear oil.

[00182] Step E: The product of step D (62 mg, 0.14 mmol) was diluted with methylene chloride (1 mL) followed by the addition of oxalyl dichloride (0.093 mL, 0.19 mmol) and 1 drop of DMF. The reaction was stirred for 30 minutes followed by the addition of 3,4-dichlorobenzenamine (46 mg, 0.28 mmol). The reaction was allowed to stir for 1 hour. The reaction mixture was loaded directly onto a 12i simul and purified on the horizon eluting with methylene chloride:MeOH (99.5:0.5 to 95:5) to yield 30 mg of tert-butyl 2-(4-(4-((3,4-dichlorophenyl)carbamoyl)phenoxy)-3-(methylsulfonamidomethyl)phenyl)acetate as a clear oil.

[00183] Step F: The product of step E (22 mg, 0.038 mmol) was diluted with methylene chloride (1 mL) followed by the addition of TFA (1 mL). After stirring for 1 hour, the reaction was concentrated, diluted with ether, sonicated and concentrated to yield 2-(4-(4-(3,4-dichlorophenyl)carbamoyl)phenoxy)-3-(methylsulfonamidomethyl)phenyl)acetic acid (15 mg, 75%
yield) as a white solid. $^1$H NMR (400 MHz, CDCl$_3$/CD$_3$OD) 7.92 (m, 1H), 7.90 (d, 2H), 7.59 (m, 1H), 7.42 (m, 2H), 7.25 (m, 1H), 7.10 (d, 2H), 6.90 (d, 1H), 4.28 (s, 2H), 3.62 (s, 2H), 2.85 (s, 3H).

Example 15

2-(4-(4-(3,4-Dichlorophenethylcarbamoyl)phenoxy)-3-(methylsulfonanidomethyl)-phenyl)acetic acid

[00184] Prepared by the method of Example 14, substituting 3,4-dichlorobenzenamine in Step E with 2-(3,4-dichlorophenyl)ethanamine. $^1$H NMR (400 MHz, CDCl$_3$/CD$_3$OD) 7.75 (d, 2H), 7.35 (m, 3H), 7.22 (d, 1H), 7.10 (d, 1H), 6.95 (d, 2H), 6.90 (d, 1H), 4.25 (s, 2H), 3.62 (m, 4H), 3.40 (s, 2H), 2.90 (t, 2H), 2.85 (s, 3H).

Example 16

2-(3-(Methylsulfonamidomethyl)-4-(4-(naphthalen-2-ylcarbamoyl)phenoxy)phenyl)-acetic acid

[00185] Prepared by the method of Example 14, substituting 3,4-dichlorobenzenamine in Step E with napthacen-2-amine. $^1$H NMR (400 MHz, CDCl$_3$/CD$_3$OD) 8.35 (s, 1H), 7.96 (d, 2H), 7.83 (m, 3H), 7.70 (d, 1H), 7.45 (m, 3H), 7.25 (d, 1H), 7.05 (d, 2H), 6.95 (d, 1H), 4.30 (d, 2H), 3.62 (s, 2H), 2.85 (s, 3H).
Example 17

2-(4-(4-(4-Fluorophenethylcarbamoyl)phenoxy)-3-(methylsulfonamidomethyl)phenyl)-acetic acid

[00186] Prepared by the method of Example 14, substituting 3,4-dichlorobenzcnamine in Step E with 2-(4-fluorophenyl)ethanamine. $^1$H NMR (400 MHz, CDCl$_3$/CD$_3$OD) 7.70 (d, 2H), 7.40 (m, IH), 7.22 (m, 3H), 7.10 (m, 2H), 6.90 (d, 2H), 6.70 (d, IH), 4.30 (s, 2H), 3.65 (m, 4H), 2.90 (t, 2H), 2.85 (s, 3H).

Example 18

2-(3-(Methylsulfonamidomethyl)-4-(4-(phenethylcarbamoyl)phenoxy)phenyl)acetic acid

[00187] Prepared by the method of Example 14, substituting 3,4-dichlorobenzcnamine in Step E with phenethylamine. $^1$H NMR (400 MHz, CDCl$_3$/CD$_3$OD) 7.70 (d, 2H), 7.40 (m, IH), 7.31 (m, IH), 7.25 (m, 5H), 6.95 (d, 2H), 6.90 (d, IH), 4.30 (s, 2H), 3.68 (t, 2H), 3.61 (s, 2H), 2.90 (t, 2H), 2.85 (s, 3H).

Example 19

2-(3-(Methylsulfonamidomethyl)-4-(4-(phenylcarbamoyl)phenoxy)phenyl)acetic acid
Prepared by the method of Example 14, substituting 3,4-dichlorobenzenamine in Step E with aniline. \( ^1H \) NMR (400 MHz, CDCl\(_3\)/CD\(_3\)OD) 7.92 (d, 2H), 7.65 (d, 2H), 7.45 (s, 1H), 7.38 (m, 2H), 7.25 (d, 1H), 7.18 (m, 1H), 7.05 (d, 2H), 6.95 (d, 1H), 4.30 (s, 2H), 3.65 (s, 2H), 2.85 (s, 3H).

Example 20

2-(4-(4-(Benzylicarbamoyl)phenoxy)-3-(methylsulfonamidomethyl)phenyl)acetic acid

Prepared by the method of Example 14, substituting 3,4-dichlorobenzenamine in Step E with benzyl amine. \( ^1H \) NMR (400 MHz, CDCl\(_3\)/CD\(_3\)OD) 7.80 (d, 2H), 7.40 (m, 1H), 7.35 (m, 4H), 7.22 (d, 1H), 6.95 (m, 3H), 6.90 (d, 1H), 4.62 (d, 2H), 4.30 (s, 2H), 3.62 (s, 2H), 2.85 (s, 3H).

Example 21

2-(4-(4-(4-Chlorophenethylcarbamoyl)phenoxy)-3-(methylsulfonamidomethyl)phenyl)-acetic acid

Prepared by the method of Example 14, substituting 3,4-dichlorobenzenamine in Step E with 2-(4-chlorophenyl)ethanamine. \( ^1H \) NMR (400 MHz, CDCl\(_3\)/CD\(_3\)OD) 7.7 (d, 2H), 7.4 (s, 1H), 7.25 (d, 2H), 7.22 (d, 1H), 7.18 (d, 2H), 6.95 (d, 2H), 6.90 (d, 1H), 6.82 (br t, 1H), 4.3 (s, 2H), 3.65 (t, 2H), 3.4 (br s, 2H), 2.9 (t, 2H), 2.85 (s, 3H).

Example 22

2-(4-(4-(2-(4-Chlorobenzylamino)-2-oxoethyl)phenoxy)-3-(methylsulfonamidomethyl)-phenyl)acetic acid
Prepared by the method of Example 14, substituting methyl 4-hydroxybenzoate in Step A with methyl 2-(4-hydroxyphenyl)acetate and substituting 3,4-dichlorobenzeneamine in Step E with 4-chlorobenzyl amine. 1H NMR (400 MHz, CDCl3/CD3OD) 7.38 (m, 1H), 7.25 (m, 4H), 7.20 (m, 3H), 6.95 (d, 2H), 6.85 (d, 1H), 4.38 (m, 2H), 4.32 (s, 2H), 3.61 (s, 2H), 3.55 (s, 2H), 2.85 (s, 3H).

Example 23

2-(4-(4-(2-(Benzylamino)-2-oxoethyl)phenoxy)-3-(methylsulfonamidomethyl)phenyl)-acetic acid

Prepared by the method of Example 14, substituting methyl 4-hydroxybenzoate in Step A with methyl 2-(4-hydroxyphenyl)acetate and substituting 3,4-dichlorobenzeneamine in Step E with benzylamine. 1H NMR (400 MHz, CDCl3/CD3OD) 7.38 (m, 1H), 7.15-7.30 (m, 8H), 6.95 (d, 2H), 6.85 (d, 1H), 4.40 (d, 2H), 4.32 (s, 2H), 3.61 (s, 2H), 3.56 (s, 2H), 2.82 (s, 3H).

Example 24

2-(3-(Methylsulfonamidoniethyl)-4-(4-2-oxo-2-(phenethylamino)ethyl)phenoxy)phenyl)-acetic acid

Prepared by the method of Example 14, substituting methyl 4-hydroxybenzoate in Step A with methyl 2-(4-hydroxyphenyl)acetate and substituting 3,4-dichlorobenzeneamine in Step E with phenethylamine. 1H NMR (400 MHz, CDCl3/CD3OD) 7.38 (m, 1H), 7.28 (m, 1H), 7.25 (m, 1H), 7.18-7.22 (s, 2H), 7.15 (d, 2H), 7.10 (d, 1H), 6.92 (d, 2H), 6.82 (d, 1H), 4.38 (s, 2H), 3.62 (s, 2H), 3.48 (m, 4H), 2.82 (s, 3H), 2.75 (t, 2H).
Example 25

2-(4-(4-(2-(Benzy1(methyl)amino)-2-oxoethyl)phenoxy)-3-(methylsulfonamidomethyl)-phenyl)acetic acid

Prepared by the method of Example 14, substituting methyl 4-hydroxybenzoate in Step A with methyl 2-(4-hydroxyphenyl)acetate and substituting 3,4-dichlorobenzonamine in Step E with N-methylbenzylamine. 

$^1$H NMR (400 MHz, CDCl$_3$/CD$_3$OD) 7.10-7.40 (m, 9H), 6.94 (m, 2H), 6.82 (m, IH), 4.60 (d, 2H), 4.35 (m, 2H), 3.75 (d, 2H), 3.62 (m, 2H), 2.97 (d, 3H), 2.82 (s, 3H).

Example 26

2-(3-(Methylsulfonamidomethyl)-4-(4-oxo-2-(phenylamino)ethyl)phenoxy)phenyl)-acetic acid

Prepared by the method of Example 14, substituting methyl 4-hydroxybenzoate in Step A with methyl 2-(4-hydroxyphenyl)acetate and substituting 3,4-dichlorobenzonamine in Step E with aniline.

$^1$H NMR (400 MHz, CDCl$_3$/CD$_3$OD) 7.55 (d, 2H), 7.30-7.35 (m, 5H), 7.18 (m, IH), 7.10 (m, IH), 6.95 (d, 2H), 6.85 (d, IH), 4.35 (s, 2H), 3.68 (s, 2H), 3.60 (s, 2H), 2.85 (s, 3H).

Example 27

2-(4-(4-Benzamidophenoxy)-3-((4-fluorophenylsulfonamido)methyl)phenyl)acetic acid

Prepared by the method of Example 1 substituting 3,4-dichlorobenzoyl chloride in Step G with benzoyl chloride. MS+ 534.9 [M + H].
Example 28

2-(4-(4-(4-Chlorobenzamido)phenoxy)-3-((4-fluorophenylsulfonamido)methyl)phenyl)-acetic acid

Prepared by the method of Example 1 substituting 3,4-dichlorobenzoyl chloride in Step G with 4-chlorobenzoyl chloride. 

$^1$H NMR (400 MHz, CD$_3$OD) 7.85 (d, 2H), 7.70 (m, IH), 7.45-7.55 (m, 5H), 7.35 (m, IH), 7.15 (m, 2H), 6.60-6.70 (m, 3H), 4.55 (s, 2H), 3.58 (s, 2H).

Example 29

2-(4-(4-(3-Chlorobenzamido)phenoxy)-3-((4-fluorophenylsulfonamido)methyl)phenyl)-acetic acid

Prepared by the method of Example 1 substituting 3,4-dichlorobenzoyl chloride in Step G with 3-chlorobenzoyl chloride. 

$^1$H NMR (400 MHz, CD$_3$OD) 7.90 (s, IH), 7.80 (d, IH), 7.65 (m, IH), 7.52 (m, 4H), 7.45 (t, IH), 7.35 (m, IH), 7.15 (m, 2H), 6.60 (m, 4H), 4.45 (s, 2H), 3.50 (br s, 2H).

Example 30

2-(4-(4-(3,4-Difluorobenzamido)phenoxy)-3-(methylsulfonamidomethyl)phenyl)acetic acid
Prepared by the method of Example 1 substituting 3,4-dichlorobenzoyl chloride in Step G with 3,4-difluorobenzoyl chloride and substituting 4-fluorobenzenc-1-sulfonyl chloride in Step I with methanesulfonyl chloride. $^1$H NMR (400 MHz, CD$_3$OD) 7.88 (m, 1H), 7.80 (m, 1H), 7.65 (d, 2H), 7.42 (m, 2H), 7.20 (m, 2H), 7.00 (d, 2H), 6.82 (m, 1H), 4.33 (s, 2H), 3.62 (s, 2H), 2.85 (s, 3H).

**Example 31**

2-(4-(4-(2-Chlorobenzamido)phenoxy)-3-(methylsulfonylamido)ethyl)phenyl)acetic acid

[00200] Prepared by the method of Example 1 substituting 3,4-dichlorobenzoyl chloride in Step G with 2-chlorobenzoyl chloride and substituting 4-fluorobenzenc-1-sulfonyl chloride in Step I with methanesulfonyl chloride. $^1$H NMR (400 MHz, CD$_3$OD) 7.68 (d, 2H), 7.40-7.55 (m, 5H), 7.20 (d, 1H), 7.05 (d, 2H), 6.85 (d, 1H), 4.35 (s, 2H), 3.65 (br s, 2H), 2.85 (s, 3H).

**Example 32**

2-(4-(4-(3,4-Dichlorobenzamido)phenoxy)-3-methoxyphenyl)acetic acid.

[00201] Prepared according to Steps E, F, G and J of Example, i. substituting methyl 2-((tert-butoxycarbonyl)aminomethyl)-4-hydroxyphenyl)acetate in Step E with methyl 2-(4-hydroxy-3-methoxyphenyl)acetate. $^1$H NMR (400 MHz, CDCl$_3$) 9.64 (s, 1H), 8.17 (d, 1H), 7.97 (dd, 1H), 7.72-7.75 (m, 4H), 7.13 (d, 1H), 6.99 (d, 1H), 6.93 (d, 1H), 6.87 (m, 2H), 3.80 (s, 3H), 3.66 (s, 2H).
Example 33

2-(4-(4-(benzyloxycarbamoyl)phenoxy)-3-(methylsulfonamidomethyl)phenyl)acetic acid

Prepared by the method of Example 14, substituting 3,4-dichlorobenzenamine in Step E with O-benzylhydroxylamine hydrochloride. \(^1\)H NMR (400 MHz, CD\textsubscript{3}OD) 7.76 (d, \(J=8.6\) Hz, 2H), 7.50 (t, \(J=6.3\) Hz, 1H), 7.33-7.48 (m, 5H), 7.23 (d, \(J=6.3\) Hz, 1H), 6.99 (d, \(J=8.7\) Hz, 2H), 6.91 (d, \(J=8.4\) Hz, 2H), 4.91 (s, 2H), 4.10 (d, \(J=6.3\) Hz, 2H), 3.60 (s, 2H), 2.85 (s, 3H).

Example 34

2-(3-Chloro-4-(4-(4-chlorophenethylcarbamoyl)phenoxy)phenyl)acetic acid

Step A: 2-(3-Chloro-4-hydroxyphenyl)acetic acid (5.0 g, 26.8 mmol) was dissolved in 30 mL of MeOH and H\textsubscript{2}SO\textsubscript{4} (0.744 ml, 13.4 mmol) was added dropwise at ambient temperature. The reaction was refluxed for four hours and then concentrated in vacuo. The residue was diluted with 150 mL of EtOAc and washed sequentially with saturated NaHCO\textsubscript{3}, water, and brine, dried over H\textsubscript{2}SO\textsubscript{4}, and concentrated in vacuo to provide methyl 2-(3-chloro-4-hydroxyphcnyl)acetate (5.16 g, 96.0% yield) as a semi-opaque thick oil.

Step B: Methyl 2-(3-chloro-4-hydroxyphcnyl)acetate (177 mg, 0.885 mmol) was diluted with DMSO (3 mL) followed by the addition of K\textsubscript{2}CO\textsubscript{3} (122 mg, 0.885 mmol) and N-(4-chlorophenethyl)-4-chloro-3-nitrobenzamide (300 mg, 0.885 mmol) (synthesized in step C). The reaction was heated to 85 °C and stirred for 12 hours. The reaction was cooled, diluted with DCM and washed with 10% aq. sodium carbonate, water and brine. The layers were separated and the organic layer was dried over H\textsubscript{2}SO\textsubscript{4}, filtered and concentrated. The material was purified using a biotage 40S cartridge eluting with DCM:MeOH (99:1) to yield methyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)-2-nitrophenoxy)-3-chlorophenyl)acetate (206 mg, 46.3% yield).
Step C: 2-(4-Chlorophenyl)ethanamine (2.3 ml, 16 mmol) was diluted with DCM (40 mL) followed by the addition of DIEA (2.9 ml, 16 mmol) and 4-chloro-3-nitrobenzoyl chloride (3.0 g, 14 mmol) in 10 mL of DCM. After stirring for 30 minutes the reaction was loaded directly onto a biotage 4OM cartridge and eluted with hexanes:ethyl acetate (2:1) to yield N-(4-chlorophenethyl)-4-chloro-3-nitrobenzamide (4.0 g, 86% yield) as a white solid.

Step D: Methyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)-2-nilrophenoxy)-3-chlorophenyl)acetate (110 mg, 0.219 mmol) was diluted with THF (1 mL) followed by the addition of Zn dust (14.3 mg, 0.219 mmol) and saturated NH₄Cl (1 mL). After stirring for 1 hour, the reaction was diluted DCM and 10% aq. sodium carbonate. The layers were separated and the organic layer was dried over MgSO₄, filtered and concentrated to yield methyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)-2-aminophenoxy)-3-chlorophenyl)acetate (102 mg, 98.6% yield).

Step E: Isobutyl nitrite (0.075 1 ml, 0.634 mmol) was diluted with DMF (1 mL), placed under nitrogen and heated to 60 °C. Methyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)-2-aminophenoxy)-3-chlorophenyl)acetate (100 mg, 0.211 mmol) in DMF (1 mL) was added dropwise and the reaction was stirred for 1 hour. The reaction was cooled, diluted with ethyl acetate and washed with 2N HCl, saturated sodium bicarbonate and brine. The organic layer was dried over MgSO₄, filtered and concentrated. The material was purified using a biotage 12i column, eluting with DCM:MeOH (99:1) to yield methyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-chlorophenyl)acetate (70 mg, 72.3% yield).

Step F: Methyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-chlorophenyl)acetate (33 mg, 0.0720 mmol) was diluted with THF (500 µL) followed by the addition NaOH (0.144 ml, 0.720 mmol) and 100 µL of water. After stirring for 2 hours, the reaction was diluted with DCM and 2N HCl. The layers were separated and the organic layer was dried over MgSO₄, filtered and concentrated to yield 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-chlorophenyl)acetic acid (19 mg, 59.4% yield) as a white solid. ³H NMR (400 MHz, CDCl₃/CD₃OD) δ 7.65 (d, 2H), 7.42 (m, IH), 7.25 (d, 2H), 7.20 (d, IH), 7.15 (d, 2H), 7.05 (d, IH), 6.85 (d, 2H), 3.65 (t, 2H), 3.60 (s, 2H), 2.90 (t, 2H).

Example 35
2-(3-cyano-4-(4-(3,4-dichlorobenzamido)phenoxy)phenyl)propanoic acid
[00209] Step A: To a stirred solution of diisopropylamine (357 µl, 2.55 mmol) in THF (3 ml) at -78 °C was added n-butyllithium (2.5M in hexancs, 1.02 ml, 2.55 mmol). The reaction was stirred for 30 minutes after which time a solution of the acetate (500 mg, 2.13 mmol) in THF (3.5 ml) was added dropwise and stirred for 20 minutes at -78 °C, then warmed to 0 °C. MeI (133 µl, 2.13 mmol) was added and the reaction stirred for an additional 30 minutes. The reaction was acidified with 2M HCl and extracted with EtOAc. The combined organics were then washed with brine and dried over MgSO₄. The residue was purified on the Biotage Horizon (40+M, 5% to 50% BiEtOAc, 21 ml-1008 ml) to give tert-butyl 2-(3-cyano-4-(4-(3,4-dichlorobenzamido)phenoxy)phenyl)propanoate (0.368 g, 1.48 mmol, 70%). ¹H NMR (400 MHz, CDCl₃) δ 7.50-7.60 (m, 2H), 7.17 (t, J=7.8 Hz, 1H), 3.63 (q, J=7.1 Hz, 1H), 4.60 (d, J=7.2 Hz, 3H), 1.40 (s, 9H).

[00210] Step B: To a stirred solution of 4-aminophenol (2.50 g, 22.9 mmol) in DMF (55 ml) was added pyridine (1.85 ml, 22.9 mmol) followed by 3,4-dichlorobenzoyl chloride (4.0 g, 19.1 mmol) in DMF (7 ml). The reaction stirred at ambient temperature overnight, then diluted with 2M HCl and EtOAc. The aqueous layer was then extracted with EtOAc and the combined organics washed with brine and dried over MgSO₄. The residue was purified on the Biotage Horizon (65+M, 5% to 75% B:EtOAc, 51 ml-2448 ml). 3,4-Dichloro-N-(4-hydroxyphenyl)benzamide was collected as a white solid (3.91 g, 13.9 mmol, 73%). ¹H NMR (400 MHz, CD³OD) δ 8.09 (s, 1H), 7.84 (d, J=8.5 Hz, 2H), 7.67 (d, J=8.6 Hz, 1H), 7.45 (d, J=8.8 Hz, 2H), 6.78 (d, J=8.4 Hz, 2H).

[00211] Step C: To a stirred solution of tert-butyl 2-(3-cyano-4-fluorophenyl)propanoate (360mg, 1.44mmol) from Step A and 3,4-dichloro-N-(4-hydroxyphenyl)benzamide (488 mg, 1.73mmol) from Step B in DMSO (4ml) was added K₂CO₃ (240 mg, 1.73 mmol). The reaction was stirred at 125 °C overnight, then cooled to ambient temperature and diluted with EtOAc and 10% aqueous sodium carbonate. The aqueous phase was extracted with EtOAc and the combined organics washed with 10% aqueous sodium carbonate and brine, dried over MgSO₄, concentrated and purified on a Biotage Horizon (40+M, 5% to 50% B:EtOAc, 21 ml-1008 ml). The appropriate fractions were then combined and concentrated to give tert-butyl 2-(3-cyano-4-(4-(3,4-dichlorobenzamido)phenoxy)phenyl)propanoate (0.476 g, 0.797 mmol, 55%). ¹H NMR (400 MHz, CDCl₃) δ 7.99 (s, 1H), 7.84 (bs, N-H), 7.72 (d, J=9.3 Hz, 1H), 7.67 (d, J=8.7 Hz, 2H), 7.60 (m, 2H), 7.42 (d, J=8.6 Hz, 1H), 7.11 (d, J=7.7, 2H), 6.83 (d, J=8.7 Hz, 1H), 3.61 (q, J=7.1 Hz, 1H), 1.45 (d, J=7.5 Hz, 3H), 1.42 (s, 9H).

[00212] Step D: To a stirred solution of tert-butyl 2-(3-cyano-4-(4-(3,4-dichlorobenzamido)phenoxy)phenyl)propanoate (25 mg, 0.049 mmol) in DCM (1 ml) was added TFA (250 µl). The reaction was stirred at ambient temperature for 4 hours and then concentrated. The crude product was purified via preparative TLC (5% MeOH/DCM) to give 2-(3-cyano-4-(4-(3,4-
dichlorobenzamido)phenoxy)phenyl)propanoic acid (0.0174 g, 0.0382 mmol, 78%). $^1$H NMR (400 MHz, CDCl$_3$): 8.04 (bs, N-H), 7.96 (s, IH), 7.64-7.71 (m, 3H), 7.61 (s, IH), 7.55 (d, J=7.7 Hz, IH), 7.44 (dd, J=8.6, 2.2 Hz, IH), 7.08 (d, J=8.9 Hz, 2H), 6.83 (d, J=8.5 Hz, 1H), 3.74 (q, J=7.4 Hz, 1H), 1.53 (d, J=6.9 Hz, 3H).

Example 36

2-(4-(4-(3,4-dichlorobenzamido)phenoxy)-3-(methylsulfonamidomethyl)phenyl)propanoic acid

[00213] Prepared by the method of Example 14 substituting methyl 4-(4-(2-tert-butoxy-2-oxoethyl)-2-cyanophenoxy)benzoate in Step B with tert-butyl 2-(3-cyano-4-(4-(3,4-dichlorobenzamido)phenoxy)phenyl)propanoate and following steps C and F. $^1$H NMR (400 MHz, CDiOD): 8.10 (s, IH), 7.85 (s, IH), 7.60-7.70 (m, 3H), 7.50 (s, IH), 7.20 (d, IH), 7.1 (d, 2H), 6.80 (d, IH), 4.30 (s, 2H), 3.75 (q, IH), 2.80(2, 3H), 1.45 (d, 3H).

Example 37

2-(4-(4-(3,4-dichlorobenzamido)phenoxy)-3-(methylsulfonamidomethyl)phenyl)-2-methylpropanoic acid

[00214] Step A: To a stirred solution of NaH (60% in oil, 195 mg, 4.88 mmol) in DMF (10 ml) at O$^0$C was added a solution of tert-butyl 2-(3-cyano-4-fluorophenyl)acetate (500 mg, 2.125 mmol) and McI (330 µl, 5.31mmol) in DMF (1 ml) dropwise. The reaction was warmed to ambient temperature, stirred overnight, and then diluted with IN HCl and EtOAc. The aqueous was extracted with EtOAc and the combined organics washed with brine and dried over MgSO$_4$. The crude concentrated product was then purified on the Biotage Horizon (40+M 5%to 50% BiEtOAc, 18 ml-864 ml) to give tert-butyl 2-(3-cyano-4-fluorophenyl)-2-methylpropanoate (0.423 g, 1.602 mmol, 75%). $^1$H NMR (400 MHz, CDCl$_3$) δ 7.56-7.63 (m, 2H), 7.17 (t, J=8.1 Hz, IH), 1.54 (s, 6H), 1.38 (s, 9H).
Step B: 2-(4-(4-(3,4-Dichlorobenzamido)phenoxy)-3-(methylsulfonamidomethyl)phenyl)-2-methylpropanoic acid was prepared from tert-butyl 2-(3-cyano-4-fluorophenyl)-2-methylpropanoate by the method of Example 35 substituting tert-butyl 2-(3-cyano-4-fluorophenyl)-2-methylpropanoate in Step B with tert-butyl 2-(3-cyano-4-fluorophenyl)-2-methylpropanoate and following steps B,C and F of Example 14.  

**Example 38**

2-(3-(Methylsulfonamidomethyl)-4-(4-(trifluoromethyl)phenylcarbamoyl)phenoxy)phenyl)acetic acid

![Chemical Structure](image)

Prepared by the method of Example 14, substituting 3,4-dichlorobenzenamine in Step E with 4-trifluoromethylbenzenamine.  

$^1$H NMR (400 MHz, CD$_2$Cl$_2$, CD$_3$OD): 8.15 (s, 1H), 7.85 (d, 1H), 7.65-7.75 (m, 3H), 7.55 (s, 1H), 7.30 (d, 1H), 7.05 (d, 2H), 6.80 (d, 1H), 4.35 (s, 2H), 2.80 (s, 3H), 1.55 (s, 6H).

**Example 39**

2-(3-(Methylsulfonamidomethyl)-4-(4-(3-(trifluoromethyl)phenylcarbamoyl)phenoxy)phenyl)acetic acid

![Chemical Structure](image)

Prepared by the method of Example 14, substituting 3,4-dichlorobenzenamine in Step E with 3-trifluoromethylbenzenamine.  

$^1$H NMR (400 MHz, CD$_2$Cl$_2$, CD$_3$OD): 8.05 (s, 1H), 7.90 (m, 3H), 7.50 (m, 1H), 7.45 (s, 1H), 7.40 (m, 1H), 7.25 (d, 1H), 7.05 (d, 2H), 6.85 (d, 1H), 4.30 (s, 2H), 3.65 (s, 2H), 1.85 (s, 3H).
Example 40

2-(4-(4-chloro-3-fluorophenylcarbamoyl)phenoxy)-3-(methylsulfonamidomethyl)phenyl)acetic acid

Prepared by the method of Example 14, substituting 3,4-dichlorobenzenamine in Step E with 4-chloro-3-fluorobenzenamine.  

$^1$H NMR (400 MHz, CD$_3$Cl$_3$, CD$_3$OD) 7.90 (d, 2H), 7.75 (m, IH), 7.30-7.45 (m, 3H), 7.25 (d, 1H), 7.05 (d, 2H), 6.95 (d, IH), 4.3 (s, 2H), 3.65 (s, 2H), 2.85 (s, 3H).

Example 41

2-(4-(4-(3-chloro-4-fluorophenethylcarbamoyl)phenoxy)-3-(methylsulfonamidomethyl)phenyl)acetic acid

Prepared by the method of Example 14, substituting 3,4-dichlorobenzenamine in Step E with 3-chloro-4-fluorobenzenamine.  

$^1$H NMR (400 MHz, CD$_3$Cl$_3$, CD$_3$OD) 7.93 (d, 2H), 7.85 (m, IH), 7.55 (m, IH), 7.45 (s, IH), 7.25 (d, IH), 7.15 (t, IH), 7.05 (d, 2H), 6.85 (d, IH), 4.30 (s, 2H), 3.65 (s, 2H), 2.85 (s, 3H).

Example 42

2-(4-(4-(4-chlorophenethylcarbamoyl)phenoxy)phenyl)acetic acid
[00220] Step A: 2-(4-hydroxyphenyl)acetic acid (1.0 g, 6.57 mmol) was diluted with THF (4 mL) followed by the addition of Reactant 2 (2.63 g, 13.1 mmol). The reaction was stirred for hours 12 hours. The reaction was filtered and loaded directly onto a biolage 4OM cartridge eluting with hexanes:ethyl acetate (3:1) to yield tert-butyl 2-(4-hydroxyphenyl)acetate (800 mg, 58.4% yield) as a clear oil that later solidified to a white solid.

[00221] Step B: 2-(4-chlorophenyl)ethanamine (0.321 ml, 2.27 mmol) was diluted with DCM (10 mL) followed by the addition of DIEA (d 0.742) (0.395 ml, 2.27 mmol) and 4-fluorobenzoyl chloride (0.231 ml, 1.89 mmol). After stirring for 30 minutes the reaction was loaded directly onto a biolage 4OS cartridge and eluted with hexanes:ethyl acetate (2:1) to yield N-(4-chlorophenethyl)-4-fluorobenzamide (393 mg, 74.8% yield) as a white solid.

[00222] Step C: Tert-butyl 2-(4-hydroxyphenyl)acetate (200 mg, 0.960 mmol) was diluted with DMSO (4 mL) followed by the addition of K$_2$CO$_3$ (133 mg, 0.960 mmol) and N-(4-chlorophenethyl)-4-fluorobenzamide (267 mg, 0.960 mmol). The reaction was stirred at 85°C overnight, and then stirred at 138°C for 12 hours. The reaction was cooled to ambient temperature, diluted with DCM and 10% aq. sodium carbonate. The layers were separated and the organic layer was dried over MgSO$_4$, filtered and concentrated. The crude material was purified by silica gel chromatography, eluting with hexanes:ethyl acetate (4:1) to yield tert-butyl 2-(4-(4-chlorophenethyl)carbamoyl)phenoxy)phenyl)acetate (20 mg, 4.47% yield) as an off white solid.

[00223] Step D: Tert-butyl 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)phenyl)acetate (20 mg, 0.043 mmol) was diluted with DCM (1 mL) followed by the addition of TFA (1 mL). After stirring for 2 hours, the reaction was concentrated, diluted with ether and concentrated to yield 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)phenyl)acetic acid (17 mg, 97% yield) as a white solid.

$^1$H NMR (400 MHz, CD$_2$Cl$_2$, CD$_3$OD) 7.70 (d, 2H), 7.30 (m, 4H), 7.19 (m, 2H), 7.00 (m, 4H), 3.62 (m, 4H), 2.90 (t, 2H).

Example 43

2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-fluorophenyl)acetic acid

[00224] Step A: 2-(3-Fluoro-4-hydroxyphenyl)acetic acid (1.0 g, 5.88 mmol) was diluted with THF:MeOH (3:1) (10 mL) followed by the addition of TMSCH$_2$N$_2$ (5.88 ml, 11.8 mmol). After
stirring for 1 hour, the reaction was quenched with 2N HCl and diluted with DCM. The layers were separated and the organic layer was dried over MgSO₄, filtered and concentrated. The material was purified by silica gel chromatography, eluting with hexanes:ethyl acetate (2:1) to yield methyl 2-(3-fluoro-4-hydroxyphenyl)acetate (700 mg, 64.7% yield) as a clear oil.

[00225] Step B: 2-(4-Chlorophenyl)ethanamine (2.3 ml, 16 mmol) was diluted with DCM (40 mL) followed by the addition of DIEA (2.9 ml, 16 mmol) and 4-chloro-3-nitrobenzoic chloride (3.0 g, 14 mmol) dropwise in 10 mL of DCM. After stirring for 30 minutes the reaction was loaded directly onto a silica gel column and eluted with hexanes:ethyl acetate (2:1) to yield N-(4-chlorophenethyl)-4-chloro-3-nitrobenzamide (4.0 g, 86% yield) as a white solid.

[00226] Step C: Methyl 2-(3-fluoro-4-hydroxyphenyl)acetate (prepared in Step A; 163 mg, 0.885 mmol) was diluted with DMSO (3 mL) followed by the addition of K₂CO₃ (122 mg, 0.885 mmol) and N-(4-chlorophenethyl)-4-chloro-3-nitrobenzamide (prepared in Step B; 300 mg, 0.885 mmol). The reaction was stirred at 80°C for 12 hours. The reaction was cooled, diluted with DCM and washed with 10%aq. sodium carbonate, water and brine. The layers were separated and the organic layer was dried over MgSO₄, filtered and concentrated. The material was purified by silica gel chromatography, eluting with hexanes:acetone (2:1) to yield methyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)-2-aminophenoxy)-3-fluorophenyl)acetate (200 mg, 46.4% yield).

[00227] Step D: Methyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)-2-nitrophenoxy)-3-fluorophenyl)acetate (100 mg, 0.205 mmol) was diluted with THF (2 mL) followed by the addition of Zn dust (13.4 mg, 0.205 mmol) and saturated aq. NH₄Cl (1 mL). After stirring for 1 hour, the reaction was diluted with ethyl acetate and 10%aq sodium carbonate. The layers were separated and the organic layer was dried over MgSO₄, filtered and concentrated to yield methyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)-2-aminophenoxy)-3-fluorophenyl)acetate (93 mg, 99.1% yield).

[00228] Step E: Isobutyl nitrile (0.060 ml, 0.51 mmol) was diluted with DMF (2 mL), placed under nitrogen and heated to 60°C followed by the addition of methyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)-2-aminophenoxy)-3-fluorophenyl)acetate (93 mg, 0.20 mmol) in 500 μL of DMF. The reaction was stirred 30 minutes and then cooled. The reaction was diluted with ethyl acetate and washed with 2N HCl and saturated sodium bicarbonate. The layers were separated and the organic layer was dried over MgSO₄, filtered and concentrated. The material was purified by silica gel chromatography, eluting with hexanes:ethyl acetate (2:1) to yield methyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-fluorophenyl)acetate (35 mg, 39% yield).

[00229] Step F: Methyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-fluorophenyl)acetate (32 mg, 0.072 mmol) was diluted with dioxane (1 mL) followed by the addition of NaOH (0.072 ml, 0.36 mmol) and 200 μL of water. After stirring for 3 hours, the reaction was...
diluted with ethyl acetate and 2N HCl. The organic layer was dried over MgSO₄, filtered and concentrated to yield 2-(4-(4-(2-tert-butoxy-2-oxoethyl)carbamoyl)phenoxy)-3-fluorophenyl)acetic acid (15 mg, 48% yield) as a white solid. ¹H NMR (400 MHz, CD₂Cl₂, CD₃OD) 7.70 (d, 2H), 7.25 (d, 2H), 7.19 (m, 3H), 7.10 (m, 2H), 6.95 (d, 2H), 3.65 (m, 4H), 2.90 (t, 2H).

Example 44

2-(3-cyano-4-(4-chlorophenethylcarbamoyl)phenoxy)phenyl)acetic acid

[00230] Step A: A flask was charged with tert-buty1 2-(3-cyano-4-fluorophenyl)acetate (9.410 g, 40.00 mmol), methyl 4-hydroxybenzoate (7.303 g, 48.00 mmol), K₂CO₃ (6.634 g, 48.00 mmol), and DMSO (160 mL). The mixture was heated to 90 °C under a nitrogen atmosphere for 17 hours. The mixture was cooled to ambient temperature and poured into a mixture of EtOAc (250 mL) and 10% K₂CO₃ solution (250 mL). The resulting insoluble residue was dissolved in water and added to the EtOAc-aqueous mixture. The mixture was stirred for 1 hour and layers were separated. The aqueous layer was extracted with EtOAc, and the combined extracts were washed with saturated K₂CO₃, water, and brine, dried over MgSO₄, filtered through a Celite pad, and concentrated under reduced pressure to give 14.7 g of crude product as an oil. The crude material was purified by silica gel chromatography to provide methyl 4-(4-(2-tert-butoxy-2-oxoethyl)-2-cyanophenoxy)benzoate (11.6 g, 79%) as a white solid.

(00231) Step B: Methyl 4-(4-(2-tert-butoxy-2-oxoethyl)-2-cyanophenoxy)benzoate (11.60 g, 31.57 mmol) was dissolved in dioxane (160 mL) and the solution was cooled to 10 °C in an ice bath. LiOH·H₂O, 1M (37.89 mL, 37.89 mmol) was added to the solution and the mixture was stirred at ambient temperature for 5 hours. The mixture was diluted with 2N HCl (100 mL) and CH₂Cl₂ (200 mL). Layers were separated and aqueous layer was extracted with CH₂Cl₂. The combined extracts were washed with brine (100 mL), dried over MgSO₄, filtered through a Celite pad and concentrated under reduced pressure. The crude material was purified by silica gel chromatography to provide 4-(4-(2-tert-butoxy-2-oxoethyl)-2-cyanophenoxy)benzoic acid (7.29 g) as a white solid.

[00232] Step C: To 4-(4-(2-tert-butoxy-2-oxochyl)-2-cyanophenoxy)benzoic acid (0.34 g, 0.962 mmol), 2-(4-chlorophenyl)ethanamine (0.165 g, 1.06 mmol) in DMF (5 mL) was added diisopropylamine (0.200 ml, 1.15 mmol) and HBTU (0.149 g, 1.15 mmol). The reaction was stirred
al ambient temperature for 90 minutes. The reaction was diluted with water and the product extracted into ethyl acetate. The combined organic layers were dried (MgSO₄), filtered and concentrated to give tert-butyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-cyanophenyl)acetate (0.40 g, 85%) as a white solid after column chromatography.

**Step D:**
To tert-butyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-cyanophenyl)acetate (4.40 g, 8.96 mmol) in DCM (20 ml) was treated with TFA (20 ml). After stirring for 2 hours. The reaction mixture was concentrated and the crude material was purified by silica gel chromatography using a gradient of 0.5% MeOH/DCM containing 0.5% AcOH to provide 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-cyanophenyl)acetic acid (3.30 g, 84.7% yield). ¹H NMR (400 MHz, CD₃OD) 7.85 (d, 2H), 7.65 (s, 1H), 7.45 (d, 1H), 7.35 (s, 1H), 7.25 (d, 2H), 7.20 (d, 2H), 6.95 (d, 1H), 3.62 (m, 4H), 2.90 (t, 2H).

**Example 45**
2-(3-cyano-4-(4-(2,4-dichlorophenethylcarbamoyl)phenoxy)phenyl)acetic acid

[00234]  Prepared by the method of Example 44 substituting 2-(2,4-dichlorophenyl)ethanamine for 2-(4-chlorophenyl)ethanamine in Step D. ¹H NMR (400 MHz, CD₃Cl₃, CD₂OD) 7.79 (d, 2H), 7.65 (m, 1H), 7.45 (d, 1H), 7.40 (m, 1H), 7.21 (m, 2H), 7.10 (d, 2H), 6.85 (d, 1H), 3.65 (m, 4H), 3.05 (t, 2H).

**Example 46**
2-(3-bromo-4-(4-(2,4-dichlorophenethylcarbamoyl)phenoxy)phenyl)acetic acid

[00235] Step A: N-(4-chlorophenethyl)-4-hydroxybenzamide (1.5 g, 5.4 mmol) was diluted with DMSO (15 mL) followed by the addition of K₂CO₃ (0.89 g, 6.4 mmol) and 3-bromo-4-
fluorobenzaldehyde (1.0 g, 4.9 mmol). The reaction was stirred at 85°C overnight and then cooled to ambient temperature. The reaction mixture was diluted with ethyl acetate and washed with twice with 10% sodium carbonate, water and brine, and then concentrated. The crude material was purified by silica gel chromatography eluting with hexanes:ethyl acetate (1:1) and then 100% ethyl acetate to yield N-(4-chlorophenethyl)-4-(2-bromo-4-formylphenoxy)benzamide (1.6 g, 71% yield).

**Step B:** N-(4-chlorophenethyl)-4-(2-bromo-4-formylphenoxy)benzamide (1.6 g, 3.5 mmol) was diluted with THF (10 mL) followed by the addition of N,N,N-trimethyl(phenyl)methanaminium hydroxide (0.79 mL, 1.7 mmol) and methylsulfinyl(methylthio)methane (0.87 g, 7.0 mmol). The reaction was stirred at 70°C for 2 hours. The reaction mixture was loaded directly onto a silica gel column and eluted with DCM:MeOH (98:2) to yield (Z)-N-(4-chlorophenethyl)-4-(2-bromo-4-(2-(methylsulfinyl)-2-(methylthio)vinyl)phenoxy)benzamide (1.9 g, 96% yield).

**Step C:** (Z)-N-(4-chlorophenethyl)-4-(2-bromo-4-(2-(methylsulfinyl)-2-(methylthio)vinyl)phenoxy)benzamide (2.0 g, 3.5 mmol) was treated with HCl (8.9 mL, 18 mmol) in ethanol. The reaction was stirred at 70°C for 2 hours. The reaction was cooled and loaded directly onto a silica gel column eluting with hexanes:ethyl acetate (3:1) to yield ethyl 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-bromophenyl)acetate.

**Step D:** Ethyl 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-bromophenyl)acetate (30 mg, 0.058 mmol) was diluted with dioxane (500 µL) followed by the addition of NaOH (0.093 mL, 0.46 mmol) and 200 µL of water. After stirring for 3 hours, the reaction was diluted with ethyl acetate and 2N HCl. The layers were separated and the organic layer was dried over MgSO₄, filtered and concentrated to yield 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-bromophenyl)acetic acid (24 mg, 85% yield) as a white solid. ¹H NMR (400 MHz, CD₂Cl₂, CD₃OD) 7.70 (d, 2H), 7.60 (s, 1H), 7.22-7.32 (m, 3H), 7.19 (d, 2H), 7.05 (d, 1H), 6.90 (d, 2H), 3.62 (m, 4H), 2.90 (l, 2H).

**Example 47**

2-(4-(4-chlorophenethyl)carbamoyl)phenoxy)3,5-dimethylphenyl)acetic acid

**Example 47**

Prepared by the method of Example 46 substituting 4-fluoro-3,5-dimethylbenzaldehyde for 3-bromo-4-fluorobenzaldehyde in step A. ¹H NMR (400 MHz, CD₂Cl₂, CD₃OD) 7.60 (d, 2H),
Example 48

2-(4-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3-methylphenyl)acetic acid

[00240] Step A: Ethyl 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-bromophenyl)acetate (Example 46 step C: 30 mg, 0.058 mmol) was diluted with THF (1 mL) followed by the addition of bis(tri-t-butylphosphine)palladium (0) (3.0 mg, 0.0058 mmol) and methylzinc chloride (0.087 ml, 0.17 mmol). After stirring for 2 hours, the reaction was loaded directly onto a silica gel column, eluting with hexanes/ethyl acetate (3:1) to yield ethyl 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-methylphenyl)acetate (20 mg, 76% yield) as a clear oil.

[00241] Step B: Ethyl 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-methylphenyl)acetate (20 mg, 0.0443 mmol) was diluted with dioxane (500 µL) followed by the addition of NaOH (0.0885 ml, 0.443 mmol) and 200 µL of water. After stirring for 3 hours, the reaction was diluted with ethyl acetate and 2N HCl. The layers were separated and the organic layer was dried over MgSO₄, filtered and concentrated to yield 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-methylphenyl)acetic acid (16.0 mg, 85.3% yield). 1H NMR (400 MHz, CDCl₃, CD₃OD) 7.62 (d, 2H), 7.30 (d, 2H), 7.10-7.22 (m, 4H), 6.92 (d, 1H), 6.85 (d, 2H), 3.65 (t, 2H), 3.60 (s, 2H), 2.90 (t, 2H), 2.15 (s, 6H).

Example 49

2-(4-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3(thiophen-2-yl)phenyl)acetic acid
[00242] Step A: Ethyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-bromophenyl)acetate (Example 46 step C; 24 mg, 0.046 mmol) was diluted with THF (1 mL) followed by the addition of bis(tri-ethylphosphine)palladium (0) (2.4 mg, 0.0046 mmol) and 2-thienylzinc bromide (0.23 mL, 0.12 mmol). After stirring for 2 hours, the reaction was purified by silica gel chromatography, eluting with hexanes:ethyl acetate (3:1) to yield ethyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-bromophenyl)acetate (20 mg, 83% yield) as a white solid. MS ESI negative M-H = 485.

[00243] Step B: Ethyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-(thiophen-2-yl)phenyl)acetate (20 mg, 0.038 mmol) was diluted with dioxane (500 µL) followed by the addition of NaOH (0.052 mL, 0.26 mmol) and 200 µL of water. After stirring for 3 hours, the reaction was diluted with ethyl acetate and 2N HCl. The layers were separated and the organic layer was dried over MgSO₄, filtered and concentrated to yield 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-(thiophen-2-yl)phenyl)acetic acid (7 mg, 37% yield) as a white solid. ¹H NMR (400 MHz, CDCl₃, CD₂OD) δ 7.69 (s, 1H), 7.64 (d, 2H), 7.45 (d, 1H), 7.30 (d, 2H), 7.22 (d, 1H), 7.15 (d, 2H), 6.98-7.05 (m, 2H), 6.90 (d, 2H), 3.65 (m, 4H), 2.90 (t, 2H).

Example 50

2-(6-(4-(4-chlorophenethyl)carbamoyl)phenoxy)biphenyl-3-yl)acetic acid

[00244] Step A: Ethyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-bromophenyl)acetate (Example 46 step C; 24 mg, 0.046 mmol) was diluted with THF (1 mL) followed by the addition of bis(tri-ethylphosphine)palladium (0) (2.4 mg, 0.0046 mmol) and phenylzinc iodide (0.23 mL, 0.12 mmol). After stirring for 2 hours, the reaction was loaded directly onto a silica gel column and eluted with hexanes:ethyl acetate (3:1) to yield Ethyl 2-(6-(4-(4-chlorophenethyl)carbamoyl)phenoxy)biphenyl-3-yl)acetate (15 mg, 63% yield) as a clear oil.

[00245] Step B: Ethyl 2-(6-(4-(4-chlorophenethyl)carbamoyl)phenoxy)biphenyl-3-yl)acetate (10 mg, 0.0195 mmol) was diluted with dioxane (1 mL) followed by the addition of NaOH (0.0389 mL, 0.195 mmol) and 200 µL of water. After stirring for 2 hours, the reaction was diluted with ethyl acetate and 2N HCl. The layers were separated and the organic layer was dried over MgSO₄, filtered and concentrated to yield 2-(6-(4-(4-chlorophenethyl)carbamoyl)phenoxy)biphenyl-3-yl)acetic acid (1.6 mg, 16.9% yield) as a white solid. MS ESI negative M-H = 485.
Example 51

2-(6-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3'-(methylsulfonyl)biphenyl-3-yl)acetic acid

[00246] Step A. Ethyl 2-(4-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3-bromo-phenyl)acetate (Example 46 step C; 100 mg, 0.193 mmol), 3-(methanesulfonyl)phenylboronic acid (58.1 mg, 0.290 mmol), K$_2$CO$_3$ (80.2 mg, 0.580 mmol) and Pd(PPh$_3$)$_4$ (22.4 mg, 0.0193 mmol) were diluted with dioxane (2 mL) and water (1 mL). The reaction was purged three times with nitrogen and stirred at 60 $^\circ$C overnight. The reaction was cooled and loaded directly onto a silica gel column eluting with hexanes:ethyl acetate (2:1) to yield ethyl 2-(6-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3'-(methylsulfonyl)biphenyl-3-yl)acetate (80 mg, 69.8% yield).

(00247) Step B: Ethyl 2-(6-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3'-(methylsulfonyl)biphenyl-3-yl)acetate (80 mg, 0.135 mmol) was diluted with dioxane (1 mL) followed by the addition of NaOH (0.270 ml, 1.35 mmol) and 300 µL of water. After stirring for 2 hours, the reaction was diluted with ethyl acetate and 2N HCl. The layers were separated and the organic layer was dried over MgSO$_4$, filtered and concentrated. The material was purified using a biotage 12i cartridge eluting with 1-4% methanol/DCM to yield 2-(6-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3'-(methylsulfonyl)biphenyl-3-yl)acetic acid (5 mg, 6.56% yield). $^1$H NMR (400 MHz, CD$_3$Cb, CD$_3$OD) 8.05 (s, 1H), 7.81 (d, 1H), 7.78 (d, 1H), 7.50-7.60 (m, 3H), 7.42 (s, 1H), 7.38 (d, 1H), 7.25 (d, 2H), 7.19 (d, 2H), 7.05 (d, 1H), 6.85 (d, 1H), 3.75 (s, 2H), 3.62 (q, 2H), 3.0 (s, 3H), 2.90 (t, 2H).

Example 52

2-(4-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3-cyclopropylphenyl)acetic acid
Step A: A flask was charged with cyclopropyl magnesium bromide (29.6 ml, 14.8 mmol) and placed under nitrogen. Zinc chloride (14.8 ml, 14.8 mmol) was added and the reaction was stirred for 20 minutes. 3-Bromo-4-fluorobenzaldehyde (1.0 g, 4.93 mmol) and bis(tri-t-butylphosphinc)palladium (0) (0.126 g, 0.246 mmol) were diluted in 600 µL of THF and added to the reaction mixture. After stirring for 4 hours, the reaction was heated to 50°C and stirred overnight. The reaction was cooled and quenched with saturated NH₄Cl and extracted with DCM. The organic layer was dried over MgSO₄, filtered and concentrated to yield 2-(4-(4-((4-chlorophenethyl)cyclopropylphenyl)acetate (14.8 mmol), 78% yield).

Step B: N-(4-Chlorophenethyl)-4-hydroxybenzamide (504 mg, 1.83 mmol) was diluted with DMSO (8 mL) and K₂CO₃ (379 mg, 2.74 mmol) and 3-cyclopropyl-4-fluorobenzaldehyde (300 mg, 1.83 mmol) were added. The reaction was stirred at 85°C overnight. The reaction was cooled to ambient temperature, diluted with ethyl acetate and washed with twice with 10% sodium carbonate, water and brine, and concentrated. The crude material was purified by silica gel chromatography eluting with hexanes:ethyl acetate (3:1) to yield N-(4-chlorophenethyl)-4-(2-cyclopropyl-4-formylphenoxy)benzamide (160 mg, 20.9% yield).

Step C: N-(4-Chlorophenethyl)-4-(2-cyclopropyl-4-formylphenoxy)benzamide (160 mg, 0.381 mmol) was diluted with THF (3 mL) followed by the addition of N,N,N-triethyl(phenyl)methanaminium hydroxide (0.0866 ml, 0.191 mmol) and methylsulfinyl(methylthio)methane (94.7 mg, 0.762 mmol). The reaction was heated to 70°C and stirred for 2 hours. The reaction was cooled and loaded directly onto silica gel column, eluting with ethyl acetate to yield (Z)-N-(4-chlorophenethyl)-4-(2-cyclopropyl-4-(2-(methylsulfanyl)-2-(methylthio)vinyl)phenoxy)benzamide (100 mg, 49.9% yield).

Step D: (Z)-N-(4-chlorophenethyl)-4-(2-cyclopropyl-4-(2-(methylsulfanyl)-2-(methylthio)vinyl)phenoxy)benzamide (100 mg, 0.190 mmol) was diluted with HCl (0.950 ml, 1.90 mmol), heated to 70°C and stirred for 4 hours. The reaction was cooled and loaded directly onto a biotage 25 cartridge and eluted with hexanes:ethyl acetate (3:1) to yield ethyl 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-cyclopropylphenylacetate (70 mg, 77.0% yield) as a white solid.

Step E: Ethyl 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-cyclopropylphenylacetate (70 mg, 0.146 mmol) was diluted with dioxane (1 mL) followed by the addition of NaOH (0.293 ml, 1.46 mmol) and water (300 µL). After stirring for 3 hours, the reaction was diluted with ethyl acetate and 2N HCl. The layers were separated and the organic layer was dried over MgSO₄, filtered and concentrated to yield 2-(4-(4-(4-chlorophenethyl)
carbamoyl)phenoxy)-3-cyclopropylphenyl)acetic acid (50 mg, 75.9% yield) as a white solid. 

$^1$H NMR (400 MHz, CD$_3$Cl$_3$, CD$_3$OD) 7.65 (d, 2H), 7.30 (d, 2H), 7.15 (d, 2H), 7.10 (d, 1H), 6.90 (m, 4H), 3.65 (t, 2H), 3.60 (s, 2H), 2.00 (t, 2H), 2.05 (m, 1H), 0.80 (m, 2H), 0.62 (m, 2H).

Example 53

2-(4-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3-ethylphenyl)acetic acid

[00253] Step A: Ethyl 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-bromophenyl)acetate (Example 46 step C; 30 mg, 0.058 mmol) was diluted with THF (1 mL) followed by the addition of 1,1-bis(diphenylphosphino)ferrocenedichloropalladium(II) (4.8 mg, 0.0058 mmol) and diethylzinc (0.13 ml, 0.15 mmol). After stirring for 4 hours, the reaction was loaded directly onto a silica gel column, eluting with 5-50% ethyl acetate/hexane to yield ethyl 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-ethylphenyl)acetate (10 mg, 37% yield).

[00254] Step B: Ethyl 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-ethylphenyl)acetate (10 mg, 0.0215 mmol) was diluted with dioxane (500 µL) followed by the addition of NaOH (0.0429 ml, 0.215 mmol) and 5 drops of water. After stirring for 3 hours, the reaction was diluted with ethyl acetate and 2N HCl, and the layers were separated. The organic layer was dried over MgSO$_4$, filtered, and concentrated. The crude material was purified by silica gel chromatography eluting with 10%MeOH/DCM to yield 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-ethylphenyOAcetic acid (2 mg, 21.3% yield). (400 MHz, CD$_3$Cl$_3$, CD$_3$OD) 7.65 (d, 2H), 7.30 (d, 2H), 7.10-7.25 (m, 4H), 6.90 (m, 3H), 3.62 (m, 2H), 3.40 (s, 1H), 2.90 (t, 2H), 2.55 (q, 2H), 1.15 (t, 3H).

Example 54

2-(6-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-4′-(methylsulfonyl)biphenyl-3-yl)acetic acid
Step A: Ethyl 2-(4-(4-((4-chlorophenyl)carbamoyl)phenoxy)-3-bromophenyl)acetate

(Example 46 step C; 40 mg, 0.077 mmol), K₂CO₃ (32 mg, 0.23 mmol) and 4-(methylsulfonyl)phenylboronic acid (23 mg, 0.12 mmol) were diluted with dioxane (1 mL)/water (300 µL) followed by the addition of Pd(PPh₃)₄ (8.9 mg, 0.0077 mmol). The reaction was purged with nitrogen and stirred at 55°C for 12 hours. The reaction was cooled and concentrated. The residue was taken up in minimal DCM and purified by silica gel chromatography, eluting with hexanes/ethyl acetate (1:1) to yield ethyl 2-(6-(4-(4-chlorophenethylcarbamoyl)phenoxy)-4'-(methylsulfonyl)biphenyl-3-yl)acetate (20 mg, 44% yield) as a clear oil.

Step B: Ethyl 2-(6-(4-(4-chlorophenethylcarbamoyl)phenoxy)-4'-(methylsulfonyl)biphenyl-3-yl)acetate (20 mg, 0.0338 mmol) was diluted with dioxane (1 mL) followed by the addition of NaOH (0.0676 ml, 0.338 mmol) and 300 µL of water. After stirring for 3 hours, the reaction was diluted with ethyl acetate and 2N HCl. The layers were separated and the organic layer was dried over MgSO₄, filtered and concentrated to yield 2-(6-(4-(4-chlorophenethylcarbamoyl)phenoxy)-4'-(methylsulfonyl)biphenyl-3-yl)acetic acid (10 mg, 52.5% yield). (400 MHz, CD₃Cl, CD₃OD) 7.90 (d, 2H), 7.70 (d, 2H), 7.60 (d, 2H), 7.40 (s, IH), 7.35 (d, IH), 7.25 (d, 2H), 7.15 (d, 2H), 7.05 (d, IH), 6.85 (d, 2H), 6.55 (t, IH), 3.63 (m, 4H), 3.05 (s, 3H), 2.90 (t, 2H).

Example 55

2-(3-(methylsulfonamidomethyl)-4-(4-(3-(trifluoromethyl)phenethyl)carbamoyl)phenoxy)phenyl)acetic acid

Prepared by the method of Example 14, substituting 3,4-dichlorobenzenamine in Step E with 2-(3-trifluoromethylphenyl)ethanamine. MS+ 551.1 [M + H].
Example 56

2-(3-(methylsulfonamidomethyl)-4-(4-(4-trifluoromethyl)phenethylcarbamoyl)phenoxy)phenyl)acetic acid

Prepared by reminding of Example 14, substituting 3,4-dichlorobenzenamine in Step E with 2-(4-trifluoromethylphenyl)ethyamine. MS+ 550.9 [M + 1].

Example 57

2-(4-(4-((1-(4-chlorophenyl)cyclopropyl)methylcarbamoyl)phenoxy)-3-(methylsulfonamidomethyl)phenyl)acetic acid

Prepared by the method of Example 14, substituting 3,4-dichlorobenzenamine in Step E with (1-(4-chlorophenyl)cyclopropyl)methanamine. MS - 541.1 [M - 1].

Example 58

2-(4-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3-(nicotinamidomethyl)phenyl)acetic acid

Step A: A mixture of tert-butyl 2-(3-cyano-4-fluorophenyl)acetate (1.32 g, 5.59 mmol), N-(4-chlorophenethyl)-4-hydroxybenzamide (1.85 g, 671 mmol), and potassium carbonate (0.93 g, 6.70 mmol) in DMSO (10 ml) was stirred at 90 °C for 1 day. The reaction was cooled, diluted with ethyl acetate, and washed with 10% aqueous Na₂CO₃. The aqueous layer was back extracted with
ethyl acetate. The organic washes were combined, washed with 10% Na₂CO₃ and brine, dried over sodium sulfate and concentrated. The crude material was purified by silica gel chromatography, eluting with a gradient of 5% ethyl acetate/hexanes to 60% ethyl acetate/hexanes gave tert-butyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-cyanophenyl)acetate (1.09 g, 40%).

**Step B:** To tert-butyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-cyanophenyl)acetate (1.09 g, 2.22 mmol) in 6 ml of 7 N ammonia in methanol at ambient temperature was added Raney-Ni (0.019 g) and the reaction was stirred under a balloon of hydrogen gas at ambient temperature. The reaction was filtered and concentrated to give tert-butyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-(aminomethyl)phenyl)acetate (0.160 g, 15%).

**Step C:** A mixture of tert-butyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-(aminomethyl)phenyl)acetate (0.015 g, 0.030 mmol), nicotinoyl chloride hydrochloride (0.007 g, 0.039 mmol), and triethylamine (0.013 ml, 0.091 mmol) in dichloromethane (1 ml) was stirred at ambient temperature for 1 hour. The reaction was loaded onto a silica gel sample and the product was eluted using a gradient system of 0.5% methanol/dichloromethane to 5% methanol/dichloromethane to provide tert-butyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-(nicotinamidomethyl)phenyl)acetate (0.005 g, 275%).

**Step D:** To a solution of tert-butyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-(nicotinamidomethyl)phenyl)acetate (0.005 g, 0.008 mmol) in dichloromethane (1.0 ml) was added TFA (1.0 ml) and the reaction was stirred at ambient temperature. After 1 hour the reaction was concentrated to give 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-(nicotinamidomethyl)phenyOacetic acid (0.005 g). MS -449.1 [M - CO₂H].

**Example 59**

2-(4-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3-((pyridine-3-sulfonamido)methyl)phenyl)acetic acid

Prepared by the method of Example 58, substituting nicotinoyl chloride hydrochloride in Step C with pyridine-3-sulfonyl chloride hydrochloride. MS -578.1 [M - 1].

**Example 60**

2-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3-((1-methyl-1H-imidazole-5-sulfonamido)methyl)phenyl)acetic acid
Prepared by the method of Example 58, substituting nicotinoyl chloride hydrochloride in Step C with 1-methyl-1H-imidazole-4-sulfonamide hydrochloride. MS -581.2 [M - I].

Example 61

2-(4-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3-((6-dimethylamino)nicotinamido)methyl)phenyl)acetic acid

Prepared by the method of Example 58, substituting nicotinoyl chloride hydrochloride in Step C with 6-(dimethylamino)nicotinic acid. MS -585.2 [M - 1].

Example 62

2-(4-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3-((2-(4-fluorophenylsulfonamido)acetamido)methyl)phenyl)acetic acid

Prepared by the method of Example 58, substituting nicotinoyl chloride hydrochloride in Step C with 2-(4-fluorophenylsulfonamido)acetic acid. MS -608.4 [M - CO2H].

Example 63

2-(3-((6-aminonicotinamido)methyl)-4-(4-(4-chlorophenethylcarbamoyl)phenoxy)phenyl)acetic acid
Prepared by the method of Example 58, substituting nicotinoyl chloride hydrochloride in Step C with 6-aminonicotinic acid. MS =557.1 [M - I].

Example 64

2-(4-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3-((dimethylamino)methyl)phenyl)acetic acid

Step A: To a stirred solution of tert-butyl 2-(3-(aminonicthyl)-4-(4-(phenethylcarbamoyl)phenoxy)phenyl)acetate (0.015 g, 0.030 mmol) in nictlianol (1 ml) was added acetic acid (0.012 ml, 0.212 mmol), sodium cyanoborohydride (0.010 g, 0.152 mmol) and paraformaldehyde (0.007 g, 0.152 mmol). The reaction was stirred at ambient temperature for 1 hour. The reaction was loaded directly onto a silica gel sample and the product eluted using a gradient of 0.5% methanol/dichloromethane to 5% methanol/ dichloromethane to provide tert-butyl 2-(4-(4-((4-chloroanilinyl)carbamoyl)phenoxy)-3-((dimethylamino)methyl)phenyl)acetic acid (0.005 g, 0.010 mmol).

Step B: To tert-butyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-((dimethylamino)methyl)phenyl)acetate (0.005 g, 0.010 mmol) in dichloromethane (1.0 ml) was added TFA (1.0 ml) and the reaction stirred for 1 hour at ambient temperature. The reaction was concentrated to give 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-((dimethylamino)methyl)phenyl)acetic acid (0.005 g). MS =465.1 [M - I].

Example 65

2-(4-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3-((N-methylmethylsulfonamido)methyl)phenyl)acetic acid
(00271) Step A: To a stirred solution of tert-butyl 2-(3-cyano-4-fluorophenyl)acetate (1.00 mg, 4.25 mmol) and methyl 4-hydroxybenzoate (776 mg, 5.10 mmol) in DMSO (20 ml) was added K2CO3 (704 mg, 5.10 mmol). The reaction was heated to 90 °C overnight via an oil bath. The reaction was diluted with ethyl acetate and 10% aqueous sodium carbonate. The aqueous phase was extracted with ethyl acetate, and the combined organic layers were washed with brine and dried. The crude product was purified by silica gel chromatography to give methyl 4-(4-(2-fluoro-2-oxoethyl)-2-cyanophenoxy)benzoate (1.08 g).

(00272) Step B: To a stirred solution of the methyl 4-(4-(2-(4-fluoro-2-oxoethyl)-2-cyanophenoxy)benzoate (1.086 mg, 2.96 mmol) in 7N ammonia/methanol (30 ml) under nitrogen was added Raney Nickel (25.3 mg, 0.296 mmol). The reaction was purged with a hydrogen balloon and stirred under hydrogen overnight. The reaction was filtered through GF paper and the solid catalyst was rinsed with methanol and ethyl acetate. The filtrate was concentrated, and the crude product was purified by silica gel chromatography to give methyl 4-(2-(aminomethyl)-4-(2-tert-butoxy-2-oxoethyl)phenoxy)benzoate (0.69 g).

(00273) Step C: To a stirred solution of the methyl 4-(2-(aminomethyl)-4-(2-tert-butoxy-2-oxoethyl)phenoxy)benzoate (690 mg, 1.86 mmol) in dichloromethane (6 ml) was added pyridine (225 µL, 2.78 mmol) followed by methylanesulfonyl chloride (287 µL, 3.71 mmol). The reaction was stirred at ambient temperature for 4 hours, after which time additional pyridine (1.5 eq) and methylanesulfonyl chloride (2 eq) were added. The reaction was stirred for an additional hour and then diluted with ethyl acetate and IM HCl. The aqueous layer was extracted with ethyl acetate and the combined organics washed with brine and dried over MgSO4. The crude product was then purified on the Biotage Horizon (40+M, 5% to 75% B: ethyl acetate) to give methyl 4-(4-(2-tert-butoxy-2-oxoethyl)-2-(methylsulfonamidomethyl)phenoxy)benzoate (0.754 g).

(00274) Step D: To a stirred solution of the methyl 4-(4-(2-fluoro-2-oxoethyl)-2-(methylsulfonamidomethyl)phenoxy)benzoate (745 mg, 1.65 mmol) in DMF (10 ml) was added MeI (155 µL, 2.48 mmol) followed by K2CO3 (343 mg, 2.48 mmol). The reaction was stirred at ambient temperature for 3 hours, then diluted with ethyl acetate and 2M HCl. The aqueous phase was extracted with ethyl acetate, and the combined organic layers were washed with brine and dried.
over MgSO₄. The crude mixture was purified by silica gel chromatography to give methyl 4-(4-(2-/m-butoxy-2-oxoethyl)-2-((N-methylmethan-2-ylsulfonamido)methyl)phenoxy)benzoate (0.368 g).

Step E: To a stirred solution of methyl 4-(4-(2-fc-T-butoxy-2-oxoethyl)-2-((N-methylmethan-2-ylsulfonamido)methyl)phenoxy)benzoate (370 mg, 0.797 mmol) in dioxane (8 ml) was added a solution of LiOH monohydrate (43.5 mg, 1.04 mmol) in water (2 ml) (0.1 M solution 4:1 dioxane/water). The reaction was stirred for 5 hours, then diluted with dichloromethane and 2N HCl. The aqueous phase was extracted with dichloromethane and the combined organic layers were washed with brine and dried over MgSO₄. The crude product was purified by silica gel chromatography to give 4-(4-(2-tert-butoxy-2-oxoethyl)-2-((N-methylmethan-2-ylsulfonamido)methyl)phenoxy)benzoic acid (0.253 g).

Step F: To a stirred solution of 4-(4-(2-tert-butoxy-2-oxoethyl)-2-((N-methylmethan-2-ylsulfonamido)methyl)phenoxy)benzoic acid (50 mg, 0.111 mmol) and HATU (46.5 mg, 0.122 mmol) in DMF (1 ml) was added DIEA (23.2 µL, 0.133 mmol) followed by 2-(4-chlorophenethyl)ethanamine (11.2 µL, 0.111 mmol). The reaction was diluted with water and extracted with ethyl acetate. The combined organics were washed with brine and dried over MgSO₄. The crude product was purified by silica gel chromatography to give tert-butyl 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-((N-methylmethan-2-ylsulfonamido)methyl)phenylacetate (0.0115 g).

Step G: To a stirred solution of tert-butyl 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-((N-methylmethan-2-ylsulfonamido)methyl)phenylacetate (11.5 mg, 0.019 mmol) in dichloromethane (1 ml) was added TFA (500µl). The reaction was stirred at ambient temperature for 4 hours and then concentrated. The crude product was then purified by preparative TLC (20% methanol/dichloromethane/0.5% AcOH) to give 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-((N-methylmethan-2-ylsulfonamido)methyl)phenylacetic acid (0.0123 g). MS +531.0 [M + I].

Example 66

2-(3-cyano-4-(4-(phenethylcarbamoyl)phenoxy)phenyl)acetic acid
Step A: A mixture of tert-butyl 2-(3-cyano-4-fluorophenyl)acetate (0.122 g), N-(4-chlorophenethyl)-4-hydroxybenzamide (0.150 g), and potassium carbonate (0.086 g) was dissolved in 2 mL of DMSO and stirred at 90°C. After 1 day, the reaction was cooled, loaded onto a silica gel sample and product eluted with a solvent system gradient of 0.5% methanol/dichloromethane to 5% methanol/dichloromethane to give tert-butyl 2-(3-cyano-4-(4-(phenethylcarbamoyl)phenoxy)phenyl)acetate (0.120 g).

Step B: To a solution of tert-butyl 2-(3-cyano-4-(4-(phenethylcarbamoyl)phenoxy)phenyl)acetate (0.120 g) in 2 mL of dichloromethane was added 2 mL of TFA and the reaction was stirred at ambient temperature. After 1 hour the reaction was concentrated and dried under vacuum to give 2-(3-cyano-4-(4-(phenethylcarbamoyl)phenoxy)phenyl)acetic acid (0.100 g). MS: 355.3 [M - CO2H].

Example 67
2-(4-(4-(4-chlorophenethylcarbamoyl)-3-(trifluoromethyl)phenyl)acetic acid

Step A: To a stirred solution of the 4-fluoro-3-(trifluoromethyl)benzaldehyde (177 µL, 1.30 mmol) and N-(4-chlorophenethyl)-4-hydroxybenzamide (359 mg, 1.30 mmol) in DMSO (3 mL) was added K$_2$CO$_3$ (270 mg, 1.95 mmol). The reaction was stirred at 95°C for 2 hours and then directly purified by silica gel chromatography to give N-(4-chlorophenethyl)-4-(4-formyl-2-(trifluoromethyl)phenoxy)benzamide (0.541 g).

Step B: To a solution of N-(4-chlorophenethyl)-4-(4-formyl-2-(trifluoromethyl)phenoxy)benzamide (0.225 g, 0.502 mmol) in THF (5 mL) was added methylsulfinyl(methylthio)methane (0.125 g, 1.00 mmol) followed by benzyltrimethylammonium hydroxide (0.114 mL, 0.251 mmol) and the reaction was stirred at 70°C for 1 hour. The reaction was cooled, loaded onto a silica gel sample and the product was eluted using a gradient of 0.5% methanol/dichloromethane to 15% methanol/dichloromethane. Isolated (Z)-N-(4-chlorophenethyl)-4-(4-(2-(methylsulfinyl)-2-(methylthio)vinyl)-2-(trifluoromethyl)phenoxy)benzamide (0.220 g, 79.0% yield) which by TLC appeared to be a 4:1 mixture of olefin isomers. The crude material was used directly in the next step.
Step C: To (Z)-N-(4-chlorophenethyl)-4-(2-(methylsulfinyl)-2-(methylthio)vinyl)-2-(trifluoromethyl)phenoxy)benzamide (0.220 g, 0.397 mmol) was added HCl (in ethanol) (0.993 ml, 1.99 mmol) and the reaction heated to 70°C for 1 hour. The reaction was concentrated, loaded onto silica gel and the product eluted using a gradient of 5% ethyl acetate/hexanes to 75% ethyl acetate/hexanes. Isolated ethyl 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-(trifluoromethyl)phenyl)acetate (0.140 g, 82.1% yield) as a white solid.

Step D: To a solution of ethyl 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-(trifluoromethyl)phenyl)acetate (0.165 g, 0.326 mmol) in methanol/THF (1:1), 5 ml was added LiOH·H₂O (0.0684 g, 1.63 mmol) and 3 drops of water, and the reaction was stirred for 1 hour. The reaction was diluted with ethyl acetate, washed with 2N HCl and brine, dried over magnesium sulfate and concentrated. The crude material was purified by silica gel chromatography, eluting with a gradient of 0.5% methanol/dichloromethane containing 0.5% AcOH to 7% methanol/dichloromethane containing 0.5% AcOH to provide 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-(trifluoromethyl)phenyl)acetic acid (0.112 g). MS +478.3 [M + I]. 1H NMR (400 MHz, CD₃OD) δ 8.49 (bt, NH), 7.79 (d, J = 8.7 Hz, 2H), 7.68 (s, 1H), 7.53 (d, J = 4.3 Hz, 1H), 7.28 (d, J = 8.5 Hz, 2H), 7.23 (d, J = 8.6 Hz, 2H), 7.02-7.06 (m, 3H), 3.71 (s, 2H), 3.56 (t, J = 6.8 Hz, 2H), 2.90 (t, J = 7.3 Hz, 2H).

Example 68

2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-cyanophenyl)propanoic acid

Step A: To a stirred solution of diisopropylamine in 2 ml of THF at -78°C was added n-butyl lithium (0.61 ml). The reaction was stirred for 30 minutes after which time a solution of tert-butyl 2-(3-cyano-4-fluorophenyl)acetate (0.300 g) in THF (2 ml) was added dropwise over 20 minutes at -78°C. The reaction was warmed to 0°C and then transferred a flask containing 2 ml THF and MeI (0.080 ml). The reaction was acidified with 2M HCl and extracted with ethyl acetate. The combined organics were then washed with brine and dried over MgSO₄. The concentrated product was purified by silica gel chromatography using a solvent system of 5% to 50% ethyl acetate/hexanes to provide re/7-butyl 2-(3-cyano-4-fluorophenyl)propanoate (0.140 g).
Step B: A flask was charged with ten-butyl 2-(3-cyano-4-fluorophenyl)acetate (0.070 g), N-(4-chlorophenethyl)-4-hydroxybenzamide (0.105 g), and potassium carbonate (0.047 g) in 1 ml of DMSO and stirred at 95 ℃ for one day. The reaction was taken up in dichloromethane and washed with water. The organic layer was collected, dried over MgSO₄, filtered, and concentrated. The crude material was purified by silica gel chromatography, eluting with a solvent system of 5%-80% ethyl acetate/hexanes gave /cw-butyl 2-(4-(4-(2,4-dichlorophenethyl)carbamoyl)phenoxy)-3-cyanophenylpropanoic acid (0.102 g).

Step C: A flask was charged with 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-cyanophenylpropanoate (0.098 g) in 1 ml of dichloromethane and 1 ml of TFA, and the reaction was stirred for 1 hour. The reaction was concentrated and dried under vacuum. Isolated 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-cyanophenylpropanoic acid (0.080 g). MS +449.1 [M + 1J].

Example 69
2-(3-cyano-4-(2,4-dichlorophenethyl)carbamoyl)phenoxy)phenyl)propanoic acid

Example 68
Prepared by the method of Example 68 substituting N-(4-chlorophenethyl)-4-hydroxybenzamide in step B with N-(2,4-dichlorophenethyl)-4-hydroxybenzamide. MS +483.0 [M + 1J].

Example 70
2-(4-(4-(4-chlorophenethyl)carbamoyl)-3-methoxyphenyl)acetic acid

Step A: Methyl 2-(4-hydroxy-3-methoxyphenyl)acetate (0.204 g, 1.04 mmol), N-(4-chlorophenethyl)-4-iodobenzamide (0.200 g, 0.519 mmol), 2,2,6,6-tetramethyl-3,5-heptanedione.
(0.00956 g, 0.0519 mmol), Cu(I)Cl (0.0257 g, 0.259 mmol) and Cs$_2$CO$_3$ (0.338 g, 1.04 mmol) were stirred together in NMP (2 ml) for 1 hour. The reaction was loaded onto silica gel and the product eluted using a gradient of 5% ethyl acetate in hexanes to 100% ethyl acetate/hexanes. Isolated methyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)phenoxy)-3-methoxyphenyl)acetate (0.105 g, 44.6% yield) as a yellow solid.

**Example 71**

2-(3-cyano-4-(4-(2,4-dichlorophenethyl)carbamoyl)phenoxy)-3-fluorophenoxymethyl)acetic acid

(002901) Step A: To a stirred solution of 2-fluoro-4-hydroxybenzoic acid (200mg, 1.28mmol) in DMF (3 ml) at ambient temperature were added HATU (536 mg, 1.41 mmol) and DIEA (268 µL, 1.54 mmol). The reaction was stirred for 30 minutes and then 2-(2,4-dichlorophenethyl)ethanamine (193 µL, 1.28 mmol) was added. The reaction was stirred overnight, then concentrated and diluted with water and dichloromethane. The aqueous layer was extracted with dichloromethane and the combined organic layers were washed with brine and dried over MgSO$_4$. The crude product was purified by silica gel chromatography to give N-(2,4-dichlorophenethyl)-2-fluoro-4-hydroxybenzamide (0.420 g).

(002900) Step B: To a stirred solution of N-(2,4-dichlorophenethyl)-2-fluoro-4-hydroxybenzamide (420 mg, 1.28 mmol) and rm-butyl 2-(3-cyano-4-fluorophenyl)acetate (361 mg,
1.54 mmol) in DMSO (6 ml) was added K₂CO₃ (265 mg, 1.92 mmol). The reaction was heated stirred at 70°C for one hour. The reaction was then stirred at 90°C overnight. The reaction was diluted with water and ethyl acetate. The aqueous phase was extracted with ethyl acetate and the combined organic layers were washed with 10% Na₂CO₃ and brine, dried over MgSO₄, filtered and concentrated. The crude product was purified by silica gel chromatography to give /e/-butyl 2-(4-(4-(2,4-dichlorophenethyl)carbamoyl)-3-fluorophenoxy)-3-cyanophenyl)acetic acid (0.0157 g).

[00292] Step C: To a stirred solution of /e/-butyl 2-(4-(4-(2,4-dichlorophenethyl)carbamoyl)-3-fluorophenoxy)-3-cyanophenyl)acetate (15 mg, 0.0276 mmol) in dichloromethane was added TFA. The reaction was stirred for 2 hours and then concentrated. The crude material was purified by preparative TLC (10% methanol/0.5% AcOH/dichloromethane). The appropriate section was collected and then purified a second time by preparative TLC to provide 2-(4-(4-(2,4-dichlorophenethyl)carbamoyl)-3-fluorophenoxy)-3-cyanophenyl)acetic acid (0.0042 g). ¹H NMR (400 MHz, CD₃OD) δ 7.70-7.74 (m, 2H), 7.61 (d, J = 7.8 Hz, IH), 7.43 (s, IH), 7.33 (d, J = 8.6 Hz, IH), 7.26 (d, J = 7.8 Hz, IH), 7.13 (d, J = 8.7 Hz, IH), 6.88-6.94 (m, 2H), 3.52-3.65 (m, 4H), 3.05 (t, J = 7.0 Hz, 2H).

Example 72
2-(3-cyano-4-(4-(2,6-dichlorophenethyl)carbamoyl)phenoxy)phenyl)acetic acid

[00293] Step A: TFP Resin (1.33 mmol/g; 2.872 g, 3.820 mmol) was placed in a vessel and DMA (5 mL) was added to swell the resin. The vessel was placed on a shaker for 15 minutes, and 4-(4-(2/-/e/-v-butoxy-2-oxoethyl)-2-cyanophenoxy)benzoic acid (1.500 g, 4.245 mmol), DIC (0.7311 ml, 4.669 mmol), and DMAP (0.5704 g, 4.669 mmol) were added to the mixture and the vessel was placed on the shaker. The mixture was filtered, washed with DMA, THF, dichloromethane, and ether, and air-dried to give 3.11 g of the resin bound (4-(4-(2-fert-butoxy-2-oxoethyl)-2-cyanophenoxy)benzoyl)acetate.

[00294] Step B: TFP resin bound ester (4-(4-(2-fert-butoxy-2-oxoethyl)-2-cyanophenoxy)benzoate) (0.1968 g, 0.09840 mmol) was added to a vial. THF (2 ml) was added and the resin was allowed to swell. 2-(2,6-Dichlorophenyl)ethanamine, (IM in THF; 0.08200 ml, 0.082 mmol) was added to the vial and the vial was placed on a shaker. After 16 hours, the mixture was
decanted and the resin was rinsed with THF (3 X 2ml). The combined THF solution was concentrated under reduced pressure. The residue was dried under high vacuum to give fen-butyl 2-(4-(4-((2,6-dichlorophenethyl)carbamoyl)phenoxy)-3-cyanophenyl)acetate (0.034 g), which was used in the next step without further purification.

[00295] Step C: tert-Butyl 2-(4-(4-((2,6-dichlorophenethyl)carbamoyl)phenoxy)-3-cyanophenyl)acetate (34 mg, 0.065 mmol) was dissolved in dichloromethane (1mL) and TFA (1mL) was added. After stirring for 45 minutes, the mixture was concentrated under reduced pressure to give 2-(3-cyano-4-(4-(2,6-dichlorophenethyl)carbamoyl)phenoxy)phenyl)acetic acid (0.034 g).

Example 73

2-(3-cyano-4-(4-(fluorophenethyl)carbamoyl)phenoxy)phenyl)acetic acid

[00296] Prepared by the method of Example 72 substituting 2-(2,6-dichlorophenyl)ethanamine in Step B with 2-(4-fluorophenyl)ethanamine.

Example 74

2-(3-cyano-4-(4-(methoxyphenethyl)carbamoyl)phenoxy)phenyl)acetic acid

[00297] Prepared by the method of Example 72 substituting 2-(2,6-dichlorophenyl)ethanamine in Step B with 2-(3-methoxyphenyl)ethanamine.

Example 75

2-(3-cyano-4-(4-(tert-butylphenethyl)carbamoyl)phenoxy)phenyl)acetic acid
Prepared by the method of Example 72 substituting 2-(2,6-dichlorophenyl)ethanamine in Step B with 2-(4-tort-butylphenyl)ethanamine.

Example 76

2-(3-cyano-4-(4-(4-trifluoromethylphenethylcarbamoyl)phenoxy)phenyl)acetic acid

Prepared by the method of Example 72 substituting 2-(2,6-dichlorophenyl)ethanamine in Step B with 2-(3-chlorophenyl)ethanamine.

Example 77

2-(3-cyano-4-(4-(3-chlorophenethylcarbamoyl)phenoxy)phenyl)acetic acid

Prepared by the method of Example 72 substituting 2-(2,6-dichlorophenyl)ethanamine in Step B with 2-(3-chlorophenyl)ethanamine.

Example 78

2-(3-cyano-4-(4-(3-fluorophenethylcarbamoyl)phenoxy)phenyl)acetic acid
Prepared by the method of Example 72 substituting 2-(2,6-dichlorophenyl)ethanamine in Step B with 2-(3-fluorophenyl)ethanamine.

Example 79
2-(3-cyano-4-(4-(4-methoxyphenethylcarbamoyl)phenoxy)phenyl)acetic acid

Prepared by the method of Example 72, substituting 2-(2,6-dichlorophenyl)ethanamine in Step B with 2-(4-methoxyphenyl)ethanamine.

Example 80
2-(3-cyano-4-(4-(4-methylphenethylcarbamoyl)phenoxy)phenyl)acetic acid

Prepared by the method of Example 72, substituting 2-(2,6-dichlorophenyl)ethanamine in Step B with 2-(4-methylphenyl)ethanamine.

Example 81
2-(3-cyano-4-(4-(4-methylphenethylcarbamoyl)phenoxy)phenyl)acetic acid
Example 82

2-(4-(4-(2-(4-chlorophenyl)-2-hydroxyethylcarbamoyl)phenoxy)-3-cyanophenyl)acetic acid

Example 83

2-(4-(4-(1-(4-chlorophenyl)cyclopropylcarbamoyl)phenoxy)-3-cyanophenyl)acetic acid

Example 84

2-(3-cyano-4-(4-(2-phenylcyclopropylcarbamoyl)phenoxy)phenyl)acetic acid
Prepared by the method of Example 72 substituting 2-(2,6-dichlorophenyl)ethanamine in Step B with 2-phenylcyclopropylamine.

Example 85

2-(4-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3-cyanophenyl)-2-fluoroacetic acid

Step A: tert-Butyl 2-(4-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3-cyanophenyl)acetate (0.400 g) and 4-methylbenzenesulfonyl azide (0.193 g) were dissolved in 5 ml of acetonitrile and treated with DBU (0.152 ml). The reaction was stirred for 4 hours, then concentrated, diluted with ethyl acetate and washed with water. The organic layer was dried, filtered, concentrated onto silica gel and purified by silica gel chromatography to provide tert-butyl 2-(4-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3-cyanophenyl)-2-diazoacetate (0.48 g) as a bright yellow solid.

Step B: A flask was charged with tert-butyl 2-(4-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3-cyanophenyl)-2-diazoacetate (0.108 g), 5 ml of ether and HF pyridine (0.30 g). The reaction was stirred at 40 °C for 30 minutes. The reaction mixture was diluted with ethyl acetate and neutralized with saturated aqueous bicarbonate solution. The organic layer was separated and washed with brine, dried, filtered and concentrated onto silica gel. The crude material was purified by silica gel chromatography to provide tert-butyl 2-(4-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3-cyanophenyl)-2-fluoroacetate (0.026 g) as a colorless oil.

Step C: A flask was charged with rtm-butyl 2-(4-(4-(4-chlorophenethylcarbamoyl)phenoxy)-3-cyanophenyl)-2-fluoroacetate (0.026 g), 0.5 ml of dichloromethane and 0.2 ml of TFA. The reaction was concentrated, and the residue was dissolved
in a minimal amount of dichloromethane and placed under high vacuum to give a solid. The procedure was repeated to give 2-(4-(4-(4-chlorophenethyl)carbamoyl)phenoxy)-3-cyanophenyl)-2-fluoroacetic acid (0.024 g) as a tan solid.

Example 86

2-(4-(4-(4-chlorophenethyl)cyclopropyl)methylcarbamoyl)phenoxy)-3-cyanophenyl)acetic acid

[00311] Prepared by the method of Example 72 substituting 2-(2,6-dichlorophenyl)ethanamine in Step B with (l-(4-chlorophenyl)cyclopropyl)methanamine.

Example 87

2-(4-(4-(2-(4-chlorophenyl)cyclopropylcarbamoyl)phenoxy)-3-cyanophenyl)acetic acid

[00312] Prepared by the method of Example 72 substituting 2-(2,6-dichlorophenyl)ethanamine in Step B with 2-(4-chlorophenyl)cyclopropanamine.

Example 88

2-(3-cyano-4-(4-(l,2,3,4-tetrahydronaphthalen-2-ylcarbamoyl)phenoxy)phenyl)acetic acid

[00313] Prepared by the method of Example 72 substituting 2-(2,6-dichlorophenyl)ethanamine in Step B with 1,2,3,4-tetrahydronaphthalen-2-amine hydrochloride.
Example 89

2-(3-cyano-4-(4-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylcarbamoyl)phenoxy)phenyl)acetic acid

[00314] Prepared by the method of Example 72 substituting 2-(2,6-dichlorophenyl)ethanamine in Step B with 6-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine hydrochloride.
Claims

1. A compound of general formula (I):

\[ \text{(I)} \]

or a salt thereof, wherein:

- \( R^1 \) is \( \text{Ar}^-\text{L}'^-\text{W}^-\text{I}^-\text{A}^- \);
- \( L^2 \) is \(-\text{CR}^2\text{R}^4\text{V}^-\);
- \( W \) is \(-\text{CONR}^3\text{R}^4\) or \(-\text{NR}^3\text{R}^4\text{C}^0\) ;
- \( R^8 \) and \( R^9 \) are each \( \text{H} \) or methyl;
- \( L^1 \) is \(-\text{CR}^b\text{R}^d\) or \(-\text{CH}^-\text{CH}^-\) or \(-0\text{CR}^b\text{R}^d\) provided that when \( W \) is \(-\text{NR}^3\text{C}^0\) then \( L^1 \) is \(-\text{CH}^-\text{CH}^-\);

- \( n \) and \( m \) are independently 0, 1 or 2;

- each \( R^2, R^b, R^c \) and \( R^d \) is independently \( \text{H}, \text{F}, \text{OH}, \text{methyl} \) or cyclopropyl, or \( R^c \) and \( R^d \) together with the carbon to which they are attached form a cyclopropyl ring;

- \( \text{Ar}^1 \) is phenyl or naphthyl, each of which is unsubstituted or substituted with one or more substituents selected independently from \( \text{F}, \text{Cl}, \text{CN}, \text{CF}_3, \text{CHF}_2, \text{CH}_2\text{F}, \text{SF}_2, \text{methyl}, \text{ethyl}, \text{cyclopropyl}, \text{t-butyl} \) or \( \text{OMe} \), or \( \text{Ar}^1 \) is 1,2,3,4-tetrahydronaphthyl which is unsubstituted or substituted by \( \text{methoxyl} \),

- provided that when \( \text{Ar}^1 \) is naphthyl or 1,2,3,4-tetrahydronaphthyl then \( n \) is 0;

- \( R^2 \) is \( \text{H}, \text{Cl-C}_6\) alkyl, a residue of an amino acid or dipeptide, or \( \text{CHR}^c\text{(CH}_2\text{)}_{q}\text{R}^f \);

- \( q \) is 1 to 6;

- \( R^c \) is \( \text{H}, \text{methyl} \) or \( \text{ethyl} \);

- \( R^f \) is \( \text{NR}^8\text{R}^h \) in which \( R^8 \) and \( R^h \) each independently represents a hydrogen atom or a \( \text{C}_1\text{-C}_4\) alkyl group, or \( R^8 \) and \( R^h \) together with the nitrogen atom to which they are attached form a 5-6 monocyclic heterocyclic ring optionally containing a second ring heteroatom selected from \( \text{N} \) and \( \text{O} \), wherein said heterocyclic ring is optionally substituted with one or more groups independently selected from \( \text{Cl-C}_6\) alkyl;

- \( A \) is \( \text{CN}, \text{CH}_2\text{NMe}_2, \text{CH}_2\text{NR}^3\text{C(O)R}^5 \), or \( \text{CH}_2\text{NR}^3\text{SO}_2\text{R}^6 \), \( \text{Cl}, \text{OMe} \), \( \text{(1-4C)alkyl} \), cyclopropyl, \( \text{H}, \text{F}, \text{Br}, \text{CH}_2\text{NH}(1-4\text{C} \text{alkyl}), \text{CH}_2\text{N}(1-4\text{C} \text{alkyl})_2 \), \( \text{thienyl} \), or \( \text{phenyl} \) which is unsubstituted or substituted with \( \text{SO}_2\text{Me} \);
R\(^3\) and R\(^{4b}\) are each H or methyl;  
R\(^5\) is C\(_1\)-C\(_6\) alkyl, C-C\(_6\) alkoxy, C\(_3\)-C\(_6\) cycloalkyl, hetAr\(^1\), or Ar\(^*\);  
R\(^6\) is C\(_i\)-C\(_j\) alkyl, NH(C\(_1\)-C\(_6\) alkyl), N(C\(_i\)-C\(_j\) alkyl)\(_2\), Ar\(^3\), or hetAr\(^2\);  
hetAr\(^1\) is a 6 membered heteroaryl which is unsubstituted or substituted with one  
or more groups independently selected from a halogen atom and a group of formula -NR\(^5\)R\(^{1b}\) in  
which each of R\(^5\) and R\(^{1b}\) independently represents a hydrogen atom or a (1-4C) alkyl group, or  
together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidinyl or  
mo\& holino group;  
hetAr\(^2\) is a 5-6 membered heteroaryl which is unsubstituted or substituted with  
one or more groups independently selected from C\(_1\)-C\(_4\) alkyl;  
Ar\(^2\) is phenyl which is unsubstituted or substituted with one or more groups  
individually selected from a halogen atom, CN, SF\(_5\), cyclopropyl, a C\(_p\)-C\(_4\) alkyl group, a C\(_i\)-C\(_j\)  
alkoxy group and a fluoroC\(_i\)-C\(_j\) alkyl group;  
Ar\(^3\) is as defined for Ar\(^*\);  
R\(^7\) and R\(^8\) are independently H, methyl, or F;  
R\(^9\) is H or methyl; and  
R\(^{10}\) is H or F.  

2. A compound of claim 1 having the formula Ia

\[
\text{Ia}
\]

wherein  
R\(^1\) is Ar\(^1\)'-L\(^1\)-W-L\(^2\)-;  
L\(^2\) is -(CR\(^4\)RV;  
W is -CONR\(^{30}\) or -NR\(^{3b}\)CO-;  
R\(^{3a}\) and R\(^{3b}\) are each H or methyl;  
L\(^1\) is -(CR\(^0\)RV\(^1\)-(CH=CH)\(_n\)- or -0(CR\(^0\)R\(^8\))\(_n\)-, provided that when W is -NR\(^3\)CO-  
then L\(^1\) is not -(CH=CH)\(_n\);  
n and m are independently 0, 1 or 2;  
each R\(^7\), R\(^{1b}\), R\(^5\) and R\(^{1d}\) is independently H, F, methyl or cyclopropyl, or R\(^*\) and  
R\(^b\) or R\(^c\) and R\(^d\) together with the carbon to which they are attached form a cyclopropyl ring;
A r\textsuperscript{1} is phenyl or naphthyl, each of which is unsubstituted or substituted with one or more substituents selected independently from F, Cl, CN, CF\textsubscript{3}, CHF\textsubscript{2}, CH\textsubscript{2}F, SF\textsubscript{5}, methyl, ethyl and cyclopropyl, provided that when A r\textsuperscript{1} is naphthyl then n is 0; 

R\textsuperscript{2} is H, C\textsubscript{6}-Ce alkyl, a residue of an amino acid or dipeptide, or CHR\textsubscript{i}(CH\textsubscript{2})\textsubscript{n} R\textsubscript{1}; 

q is 1 to 6; 

R\textsuperscript{e} is H, methyl or ethyl; 

R\textsuperscript{f} is NR\textsuperscript{b}R\textsuperscript{f} in which R\textsuperscript{f} and R\textsuperscript{b} each independently represents a hydrogen atom or a Ci-C\textsubscript{4} alkyl group, or R\textsuperscript{8} and R\textsuperscript{b} together with the nitrogen atom to which they are attached from a 5-6 membered heterocyclic ring optionally containing a second ring heteroatom selected from N and O, wherein said heterocyclic ring is optionally substituted with one or more groups independently selected from Ci-C\textsubscript{6} alkyl; 

A is CN, CH\textsubscript{2}NH\textsubscript{2}, CH\textsubscript{2}NR\textsuperscript{4b}C(=O)R\textsuperscript{5}, CH\textsubscript{2}NR\textsuperscript{4b}SO\textsubscript{4}R\textsuperscript{5}, Cl, OMe, (l-4C)alkyl, or cyclopropyl; 

R\textsuperscript{10} and R\textsuperscript{1b} are each H or methyl; 

R\textsuperscript{5} is Ci-C\textsubscript{6} alkyl, C\textsubscript{6} alkoxy, C\textsubscript{6}-C\textsubscript{6} cycloalkyl, hetAr\textsuperscript{1}, or Ar\textsuperscript{2}; 

R\textsuperscript{6} is Ci-C\textsubscript{6} alkyl, NH(C\textsubscript{6}-C\textsubscript{6} alkyl), N(C\textsubscript{6}-C\textsubscript{6} alkyl)\textsubscript{2}, Ar\textsuperscript{3}, or hetAr\textsuperscript{p}; 

hetAr\textsuperscript{1} is a 6 membered heteroaryl which is unsubstituted or substituted with one or more groups independently selected from a halogen atom and a group of formula -NR\textsuperscript{1b}R\textsuperscript{b} in which each of R\textsuperscript{b} and R\textsuperscript{b} independently represents a hydrogen atom or a (1-4C) alkyl group, or together with the nitrogen atom to which they are attached form a pyrrolidinyl, pipcrnidinyl or morpholino group; 

hetAr\textsuperscript{p} is a 5-6 membered heteroaryl which is unsubstituted or substituted with one or more groups independently selected from Ci-C\textsubscript{6} alkyl; 

Ar\textsuperscript{2} is phenyl which is unsubstituted or substituted with one or more groups independently selected from a halogen atom, a CN, SF\textsubscript{6}, cyclopropyl, CpC\textsubscript{4} alkyl group, a Ci-C\textsubscript{4} alkoxy group and a fluoroCi-C\textsubscript{4} alkyl group; 

Ar\textsuperscript{3} is as defined for Ar\textsuperscript{2}; and 

R\textsuperscript{7} and R\textsuperscript{8} are independently H or methyl. 

3. A compound according to claim 1 or 2, wherein -L\textsuperscript{1}-W-L\textsuperscript{2} is selected from 

-CONH-, -CH\textsubscript{2}CONH-, -CH\textsubscript{2}CH\textsubscript{2}CONH-, -CONHCH\textsubscript{2}, -CH\textsubscript{2}CONHCH\textsubscript{2}, -NHCO-, -CH\textsubscript{2}NHCO-, -NHCOCH\textsubscript{2}, -CH\textsubscript{2}CH\textsubscript{2}NHCO-, -CH\textsubscript{2}NHCOCH\textsubscript{2}, -CH\textsubscript{2}N(CH\textsubscript{3})COCH\textsubscript{2}, cyclopropylideneCH\textsubscript{2}NHCO, -CH\textsubscript{2}ONHCO-, -CH(OH)CH\textsubscript{2}NHCO- and -cyclopropylideneNHCO-. 
4. A compound according to any of claims 1-3, wherein Ar₁ is a naphthyl group or a phenyl group that is unsubstituted or substituted by one or two substituents selected independently from F, Cl, CF₃, OMe, Me, and l-Bu, or a 1,2,3,4-tetrahydronaphthyl group which is unsubstituted or substituted with OMe.

5. A compound as claimed in claim 4, wherein Ar₁ is naphthyl, phenyl, 4-fluorophenyl, 3,4-difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 4-chloro-3-fluorophenyl, 3-chloro-4-fluorophenyl, 4-trifluoromethylphenyl, 3-fluoro-4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 2,6-dichlorophenyl, 2,4-dichlorophenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-tertbutylphenyl, 3-fluorophenyl and 4-methylphenyl, 1,2,3,4-tetrahydronaphth-2-yl or 6-methoxy-1,2,3,4-tetrahydronaphth-2-yl.

6. The compound according to any of claims 1-5, wherein the 6 membered heterocarlyl group in hetAr¹ is a pyridyl group and the 5-6 membered heteroaryl in hetAr² is an imidazolyl or pyridyl group.

7. A compound as claimed in claim 6, in which R₅ is C₁-C₆ alkyl; C₁-C₆ alkoxy; C₃-C₆ cycloalkyl; pyridyl which is unsubstituted or substituted by a halogen atom or a group of formula -NR₅=R₆ in which each of R₅ and R₆ independently represents a hydrogen atom or a (1-4C) alkyl group, or together with the nitrogen atom to which they are attached form a pyrrolidinyl, pipicridinyl or morpholino group; or a phenyl group that is unsubstituted or substituted by one or two halogen atoms, and R₆ is C₁-C₆ alkyl, NH(C-C₆ alkyl), N(C-C₆ alkyl)ₒ a phenyl group that is unsubstituted or substituted by one or two halogen atoms, pyridyl or imidazolyl that is unsubstituted or substituted with a C₁-C₃ alkyl group.

8. A compound as claimed in claim 7, in which R₅ is methyl, methoxy, cyclohexyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, 6-chloro-pyrid-3-yl, 6-amino-pyrid-3-yl, 6-pyrrolidin-1-ylpyrid-3-yl or 4-fluorophenyl and R₆ is methyl, dimethylamino, 4-fluorophenyl, 2,4-dichlorophenyl, pyrid-3-yl, 1-methylimidazol-5-yl, or 6-dimethylaminopyrid-3-yl.

9. A compound as claimed in claims 1-5, in which A is selected from cyano, acetalimidomethyl, cyclohexylamidomethyl, methoxycarbonylamidomethyl, picolinamidomethyl, nicolinamidomethyl, isonico-ünamidomethyl, β-chloropyrid-S-ylamidomethyl, 6-amino-pyrid-3-ylamidomethyl, 6-pyrrolidin-1-ylpyrid-3-ylamidomethyl, 4-fluorobenzoamidomethyl, methylsulfonamidomethyl, N,N-dimethylsulfamoylamino, 4-fluorophenylsulfonamidomethyl, 2,4-dichlorophenylsulfonamidomethyl, 1-methylimidazol-5-ylsulfonamidomethyl, pyrid-3-ylsulfonamidomethyl, 6-dimethylaminopyrid-3-ylamidomethyl, 2-(4-fluorophenylsulfonamido)acetamidomethyl, dimethylaminomethyl, (N-methyl(methylsulfonamidomethyl)methyl, H, F, Br, Cl,
methyl, ethyl, cyclopropyl, \( \text{CH}_2\text{NH}_2 \), \( \text{CH}_2\text{NMe}_2 \), thienyl, phenyl, 3-methylsulfonylphenyl, and 4-methylsulfonylphenyl.

10. A compound as claimed in claim 9, in which A is selected from cyano, acetamidomethyl, cyclohexylamidomethyl, methoxycarbonylaminomethyl, picolinamidomethyl, nicotinamidomethyl, isonicotinamidomethyl, 4-fluorobenzamidomethyl, methylsulfonylamido, N,N-dimethylsulfamoylamino, 4-fluorophenylsulfonamidomethyl, 2,4-dichlorophenylsulfonamidomethyl, pyrid-3-ylsulfonamidomethyl, 6-dimethylaminopyrid-3-ylamidomethyl, 2-(4-fluorophenylsulfonamido)acetamidomethyl, dimethylaminomethyl, (N-methylmethylsulfonamido)methyl, \( \text{H, F, Br, Cl, methyl, ethyl, cyclopropyl, CH}_2\text{NH}_2 \), \( \text{CH}_2\text{NMe}_2 \), thienyl, \( \text{SO}_3\text{Me} \), phenyl, 3-methylsulfonylphenyl, and 4-methylsulfonylphenyl.

11. A compound as claimed in any one of claims 1 to 10, in which \( R^2 \) is hydrogen.

12. A compound as claimed in any one of claims 1 to 11, in which \( R^3 \) and \( R^8 \) are H.

13. A compound as claimed in any one of claims 1 or 3-12, in which \( R^3 \) is H.

14. A compound as claimed in any one of claims 1 or 3-13, in which \( R^8 \) is H.

15. A pharmaceutical composition, which comprises a compound of formula (I) as defined in any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

16. A method of treating an immunologic disorder in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of formula (I) as defined in any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof.

17. The method of claim 16, wherein the immunologic disorder is selected from inflammatory conditions, immune disorders, asthma, allergic rhinitis, eczema, psoriasis, atopic dermatitis, fever, sepsis, systemic lupus erythematosus, diabetes, rheumatoïd arthritis, multiple sclerosis, atherosclerosis, transplant rejection, inflammatory bowel disease, cancer, viral infection, thrombosis, fibrosis, flushing, Crohn's disease, ulcerative colitis, chronic obstructive pulmonary disease, inflammation, pain, conjunctivitis, nasal congestion and urticaria.

18. A compound of formula (I) as defined in any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, for use in therapy.

19. The use of a compound of formula (I) as defined in any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of an immunologic disorder.

20. A process for the preparation a compound as defined in any one of claims 1 to 14, which comprises:
(a) for a compound of formula (I) in which A is CN, R\textsuperscript{7} and R\textsuperscript{8} are independently H or Me, and R\textsuperscript{10} is H or F, racemic a corresponding compound having the formula:

![Chemical Structure (II)](image)

in which P\textsuperscript{1} represents a hydrogen atom or a carboxyl protecting group and Z' represents a leaving atom or group, with a corresponding compound having the formula:

![Chemical Structure (III)](image)

in which R\textsuperscript{10a} is H or F in the presence of a base; or

(b) for a compound of formula (I) in which A is -CH\textsubscript{2}NH\textsubscript{2}, R\textsuperscript{10} is H\textsubscript{1} and R\textsuperscript{7} and R\textsuperscript{8} are independently H or Me, reducing a corresponding compound formula (IV)

![Chemical Structure (IV)](image)

in which P\textsuperscript{2} is as defined for P\textsuperscript{1}; or

(c) for a compound of formula (I) in which A is -CH\textsubscript{2}NH\textsubscript{2}, R\textsuperscript{7} and R\textsuperscript{8} are independently H or Me, and R\textsuperscript{10} is H, cleaving a corresponding compound of formula (V)

![Chemical Structure (V)](image)
in which P^3 is as defined for P^1; or

(d) for a compound of formula (I) in which A is \( \text{CH}_2\text{NR}^3\text{C}(=\text{O})\text{R}^5 \) or \( \text{CH}_2\text{NR}^4\text{SO}_2\text{R}^6 \), 
\( \text{R}^7 \) and \( \text{R}^8 \) are independently \( \text{H} \) or \( \text{Me} \) and \( \text{R}^{10} \) is \( \text{H} \), reacting a corresponding compound of formula (VI)

\[
\begin{align*}
\text{R}^7 & \text{R}^8 \\
     & \text{ACP}^4 \\
\text{R}^9 & \text{R}^{10} \\
\end{align*}
\]

(VI)

in which P^4 is as defined for P^1; with a compound of formula R'COZ^2 or R^6SO_2Z^3 in which Z^2 and Z^3 each represents a leaving atom or group; or

(e) for a compound of formula (I) in which \( \text{R}^7 \) and \( \text{R}^8 \) are independently \( \text{H} \) or \( \text{Me} \), and \( \text{R}^{10} \) is \( \text{H} \), coupling a compound of formula (VII)

\[
\begin{align*}
\text{R}^7 & \text{R}^8 \\
     & \text{OP}^5 \\
\text{R}^9 & \text{R}^{10} \\
\end{align*}
\]

(VII)

in which P^5 is as defined for P^1, A^2 represents A or a protected form thereof and \( \text{R}^{18} \) represents H-X^b-L^2 in which X^b represents HN or OC(=O), or a reactive derivative thereof; with a compound of formula (VIII)

\[
\text{Ar}'\text{L}'\text{-X}^a\text{H}
\]

(VIII)

in which X^b represents C(=O)O or NH, or a reactive derivative thereof; or

(0) for a compound of formula (I) in which A is \( \text{H} \), \( \text{F} \) or \( \text{Cl} \), \( \text{R}^7 \) and \( \text{R}^8 \) are independently \( \text{H} \) or \( \text{Me} \), and \( \text{R}^{10} \) is \( \text{H} \), coupling a corresponding compound having the formula (IX)
in which $A^3$ is H, F or Cl, and $P^6$ is as defined for $P'$, with a corresponding compound having the formula (X)

wherein $E$ is an electron withdrawing group, in the presence of a base; and if desired removing said electron withdrawing group; or

(g) for a compound of formula (I) in which $A$ is OMe or (1-4C)alkyl, $R^7$ and $R^8$ are independently H or Me, and $R^{10}$ is H, coupling a corresponding compound having the formula (XI)

in which $A^4$ is OMe or (1-4C)alkyl, respectively, and $P^7$ is as defined for $P^1$, with a corresponding compound having the formula (XII)

in the presence of a base, in which $Z^4$ represents a leaving atom or group, and $R^{15}$ represents an electron withdrawing group convertible into a group $R^1$; or

(h) for a compound of formula (I) in which $A$ is Br or cyclopropyl, $R^7$ and $R^8$ are H, and $R^{10}$ is H, coupling a corresponding compound having the formula (XIV)
in which $Z^5$ is a leaving group or atom, with a compound having the formula (XV)

in the presence of a base, followed by converting the carbonyl group to a carboxyl group; or

(i) for a compound of formula (I) in which $A$ is methyl, thienyl, phenyl, or phenyl substituted with $SO_2Me$, $R^9$ is H, $R^7$ and $R^8$ are independently H or Me, and $R^{10}$ is H, reacting a corresponding compound having the formula (XVI)

with a compound having the formula $A^5$ZnX, in the presence of a palladium (0) catalyst, or with a compound having the formula $A^5B(OH)_2$ in the presence of a base and a palladium (0) catalyst, where $A^5$ is methyl, thienyl, phenyl, or phenyl substituted with $SO_2Me$ and $X$ is a halide; or

(j) for a compound of formula (I) in which $R^7$ is F, $R^8$ is H, and $R^{10}$ is H, treating a corresponding compound having the formula (XVII)
with hydrogen fluoride; and
removing any protecting group or groups and, if desired, forming a salt.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07C233/87 C07C255/57 C07C307/06 C07C311/06 C07C311/19
C07C317/14 C07D213/81 C07D213/82 C07D333/16 A61K31/18
A61K31/435 A61K31/165 A61K31/77 A61K31/381 A61K31/10

According to International Patent Classification (IPC) or to both national classification and IPC.

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07C  C07D  A61K  A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, CHEM ABS Data, BEILSTEIN Data, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim</th>
</tr>
</thead>
</table>

Further documents are listed in the continuation of Box C. See patent family annex.

Special categories of cited documents
A' document defining the general state of the art which is not considered to be of particular relevance
E' earlier document but published on or after the international filing date
L' document which may throw doubts on the novelty claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
O' document referring to an oral disclosure, use, exhibition or other means
P' document published prior to the international filing date but later than the priority date claimed

Date of the actual completion of the international search
15 January 2008

Date of mailing of the international search report
23/01/2008

Name and mailing address of the ISA/
European Patent Office, P B 5818 Patentlaan 2
NL-2280 HV RUISWILK
Tel (+31-70) 340-2040, Tx 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer
Gotz, Gerhard

Form PCT/ISA/210 (second sheet) (April 2005)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
</table>

Form PCT/ISA/210 (continuation of second sheet) (April 2005)
### Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ✓ Claims Nos. because they relate to subject matter not required to be searched by this Authority, namely:

   Although claims 16 and 17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. □ Claims Nos. because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. □ Claims Nos. because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. □ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. □ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. □ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. □ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- □ The additional search fees were accompanied by the applicant’s protest and, where applicable, the payment of a protest fee.
- □ The additional search fees were accompanied by the applicant’s protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- □ No protest accompanied the payment of additional search fees.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>BR 0317591 A</td>
<td>22-11-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2511214 A1</td>
<td>22-11-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1767823 A</td>
<td>15-07-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1585511 A2</td>
<td>03-05-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IS 7907 A</td>
<td>19-10-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2006516143 T</td>
<td>22-06-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 20050111314 A</td>
<td>22-06-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MX PA05006701 A</td>
<td>22-06-2005</td>
</tr>
</tbody>
</table>